CA2545399C - Protein-polysaccharide microcapsules for delivering active agents to the gi tract - Google Patents
Protein-polysaccharide microcapsules for delivering active agents to the gi tract Download PDFInfo
- Publication number
- CA2545399C CA2545399C CA2545399A CA2545399A CA2545399C CA 2545399 C CA2545399 C CA 2545399C CA 2545399 A CA2545399 A CA 2545399A CA 2545399 A CA2545399 A CA 2545399A CA 2545399 C CA2545399 C CA 2545399C
- Authority
- CA
- Canada
- Prior art keywords
- oil
- protein
- starch
- solution
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003094 microcapsule Substances 0.000 title claims description 34
- 229920001282 polysaccharide Polymers 0.000 title description 17
- 239000005017 polysaccharide Substances 0.000 title description 16
- 239000013543 active substance Substances 0.000 title description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 127
- 235000018102 proteins Nutrition 0.000 claims abstract description 47
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 47
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 47
- 235000016709 nutrition Nutrition 0.000 claims abstract description 30
- 102000011632 Caseins Human genes 0.000 claims abstract description 27
- 108010076119 Caseins Proteins 0.000 claims abstract description 27
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 25
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 25
- 235000013305 food Nutrition 0.000 claims abstract description 24
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 24
- 239000000463 material Substances 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 20
- 238000005538 encapsulation Methods 0.000 claims abstract description 20
- 235000000346 sugar Nutrition 0.000 claims abstract description 19
- 239000005018 casein Substances 0.000 claims abstract description 16
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000021240 caseins Nutrition 0.000 claims abstract description 16
- 238000003860 storage Methods 0.000 claims abstract description 11
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 10
- 235000021119 whey protein Nutrition 0.000 claims abstract description 10
- 102000014171 Milk Proteins Human genes 0.000 claims abstract description 8
- 108010011756 Milk Proteins Proteins 0.000 claims abstract description 8
- 235000021239 milk protein Nutrition 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 379
- 238000009472 formulation Methods 0.000 claims description 103
- 238000000034 method Methods 0.000 claims description 36
- 229920000294 Resistant starch Polymers 0.000 claims description 21
- 235000021254 resistant starch Nutrition 0.000 claims description 21
- 239000000839 emulsion Substances 0.000 claims description 12
- 239000012071 phase Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 abstract description 262
- 229920002472 Starch Polymers 0.000 abstract description 191
- 235000019698 starch Nutrition 0.000 abstract description 146
- 239000004615 ingredient Substances 0.000 abstract description 89
- 229920001542 oligosaccharide Polymers 0.000 abstract description 38
- 239000008393 encapsulating agent Substances 0.000 abstract description 37
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 31
- 150000001720 carbohydrates Chemical class 0.000 abstract description 21
- 235000014633 carbohydrates Nutrition 0.000 abstract description 18
- 230000000975 bioactive effect Effects 0.000 abstract description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 6
- 239000001301 oxygen Substances 0.000 abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 abstract description 6
- 239000005905 Hydrolysed protein Substances 0.000 abstract description 4
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 4
- 239000000194 fatty acid Substances 0.000 abstract description 4
- 229930195729 fatty acid Natural products 0.000 abstract description 4
- 150000004665 fatty acids Chemical class 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 239000006041 probiotic Substances 0.000 abstract description 3
- 235000018291 probiotics Nutrition 0.000 abstract description 3
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 2
- 235000019198 oils Nutrition 0.000 description 252
- 239000008107 starch Substances 0.000 description 173
- 239000000243 solution Substances 0.000 description 149
- 239000000843 powder Substances 0.000 description 140
- 235000019197 fats Nutrition 0.000 description 93
- 239000007921 spray Substances 0.000 description 82
- 238000004945 emulsification Methods 0.000 description 80
- 241001669680 Dormitator maculatus Species 0.000 description 69
- 239000006185 dispersion Substances 0.000 description 66
- 210000001072 colon Anatomy 0.000 description 34
- 229960001031 glucose Drugs 0.000 description 31
- 239000008103 glucose Substances 0.000 description 31
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 28
- 238000004519 manufacturing process Methods 0.000 description 27
- 230000008569 process Effects 0.000 description 27
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 26
- 239000011162 core material Substances 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 238000011068 loading method Methods 0.000 description 15
- 238000012545 processing Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 235000012680 lutein Nutrition 0.000 description 14
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 14
- 229960005375 lutein Drugs 0.000 description 14
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 14
- 239000001656 lutein Substances 0.000 description 14
- 229920001592 potato starch Polymers 0.000 description 14
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 14
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 14
- 150000004804 polysaccharides Chemical class 0.000 description 13
- 235000010418 carrageenan Nutrition 0.000 description 12
- 239000000679 carrageenan Substances 0.000 description 12
- 229920001525 carrageenan Polymers 0.000 description 12
- 229940113118 carrageenan Drugs 0.000 description 12
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 11
- 229920001353 Dextrin Polymers 0.000 description 10
- 239000004375 Dextrin Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 235000019425 dextrin Nutrition 0.000 description 10
- 235000020357 syrup Nutrition 0.000 description 10
- 239000006188 syrup Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 229940080237 sodium caseinate Drugs 0.000 description 9
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 8
- 210000000813 small intestine Anatomy 0.000 description 8
- 150000008163 sugars Chemical class 0.000 description 8
- 229920002261 Corn starch Polymers 0.000 description 7
- 229920002907 Guar gum Polymers 0.000 description 7
- 229940077731 carbohydrate nutrients Drugs 0.000 description 7
- 229940071162 caseinate Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 235000010417 guar gum Nutrition 0.000 description 7
- 239000000665 guar gum Substances 0.000 description 7
- 229960002154 guar gum Drugs 0.000 description 7
- 239000012460 protein solution Substances 0.000 description 7
- 241000252983 Caecum Species 0.000 description 6
- 240000003183 Manihot esculenta Species 0.000 description 6
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 6
- 102000007544 Whey Proteins Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 210000004534 cecum Anatomy 0.000 description 6
- 238000001125 extrusion Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000000700 radioactive tracer Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000021391 short chain fatty acids Nutrition 0.000 description 5
- 150000004666 short chain fatty acids Chemical class 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 101150071434 BAR1 gene Proteins 0.000 description 4
- 244000303965 Cyamopsis psoralioides Species 0.000 description 4
- 235000019759 Maize starch Nutrition 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 239000005417 food ingredient Substances 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 235000019426 modified starch Nutrition 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 3
- 239000004368 Modified starch Substances 0.000 description 3
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229920001222 biopolymer Polymers 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 235000021323 fish oil Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000009973 maize Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940100445 wheat starch Drugs 0.000 description 3
- UBEIMDKGOYBUKT-FLIQGJDUSA-N 1,2,3-trilinolenoylglycerol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)COC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC UBEIMDKGOYBUKT-FLIQGJDUSA-N 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- -1 bioactives Substances 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000009931 pascalization Methods 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010061711 Gliadin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000008892 Helianthus tuberosus Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102100040396 Transcobalamin-1 Human genes 0.000 description 1
- 101710124861 Transcobalamin-1 Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000004732 colorectal carcinogenesis Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000673 dextrose monohydrate Drugs 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 231100000613 environmental toxicology Toxicity 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 229940107604 lutein esters Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000004305 normal phase HPLC Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- CBHOWTTXCQAOID-UHFFFAOYSA-L sodium ethane formaldehyde mercury(2+) molecular iodine 2-sulfidobenzoate Chemical compound [Na+].[Hg++].C[CH2-].II.C=O.[O-]C(=O)c1ccccc1[S-] CBHOWTTXCQAOID-UHFFFAOYSA-L 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/02—Other edible oils or fats, e.g. shortenings, cooking oils characterised by the production or working-up
- A23D9/04—Working-up
- A23D9/05—Forming free-flowing pieces
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
A micro encapsulation material for use with storage unstable, therapeutic and nutritional agents which release the therapeutic and nutritional agents in predetermined locations in the gastro intestinal tract in which the encapsulation material is formed by combining a food grade treated carbohydrate with a water soluble food grade protein. The therapeutic and nutritional agents form an oil phase that is emulsified with the water dispersed or dissolved encapsulant to encapsulate the therapeutic and nutritional agents. These agents may be oils or oil soluble or oil dispersible. The agents that may be encapsulated include lipids (oils including oxygen sensitive oils, fatty acids, triglycerides) and oil soluble and oil dispersible ingredients (including pharmaceuticals, probiotics, protein therapeutics and bioactives). The protein used may include any film forming water soluble protein or hydrolysed protein and includes milk proteins such as casein and its derivatives or whey proteins. The carbohydrate component may be those containing reducing sugar groups, oligosaccharides and starches (raw, modified, resistant, acetylated, proprionylated and butylated starches).
Description
PROTEIN-POLYSACCHARIDE MICROCAPSULES FOR DELIVERING
ACTIVE AGENTS TO THE GI TRACT
This invention relates to microencapsulated formulations for delivery of nutritional and pharmaceutical agents to the gastro intestinal tract and in particular the colon.
The compositions may be used for protection and delivery of nutrients or nutraceuticals in processed foods.
Background to the invention Microencapsulation involves the packaging of small particles of solid, liquid or gas within a secondary material to form a microcapsule. It has been used for targeted delivery of drugs in the body in the pharmaceutical industry. It is increasingly being seen as a technology that offers novel food processing solutions. With the use of microencapsulation, possible undesirable Interactions between the added nutraceutical and other components in the food or its environment can be avoided and the site of release of the added component can be manipulated. The appropriate application of microencapsulation technology enables the fortification of food without affecting the taste, aroma or texture of food. It can afford protection to sensitive food ingredients and enhance the shelf-life and stability of fortified foods (Brazel, C.S. (1999) Microencapsulation: offering solutions for the food industry. Cereal Foods World 44(6): 388-393; Augustin, M.A., Sanguansri, L., Margetts, C. and Young. B. (2001) Microencapsulation of food ingredients. Food Australia 53 220-223).
Microencapsulation can serve both the purposes of the food and health industries, as it is a key technology with potential for the delivery of dietary bioactives and development of successful marketable functional foods. Addressing this challenge, requires tailoring the performance of food grade microcapsules in a food processing environment so that essential sensitive components are protected during food manufacture and the microcapsules can also meet the need for site specific delivery within the gastrointestinal tract.
Directing nutraceuticals and therapeutics of the colon is of interest for treatment of colon diseases (Rubinstein, A., Tirosh, B., Baluom, M., Nassar, T., David, A., Radai, R., Gliko-Kabir, I. And Friedman, M. (1997). The rationale for peptide drug delivery to the colon and the potential for polymeric carriers as effective tools. J.
ACTIVE AGENTS TO THE GI TRACT
This invention relates to microencapsulated formulations for delivery of nutritional and pharmaceutical agents to the gastro intestinal tract and in particular the colon.
The compositions may be used for protection and delivery of nutrients or nutraceuticals in processed foods.
Background to the invention Microencapsulation involves the packaging of small particles of solid, liquid or gas within a secondary material to form a microcapsule. It has been used for targeted delivery of drugs in the body in the pharmaceutical industry. It is increasingly being seen as a technology that offers novel food processing solutions. With the use of microencapsulation, possible undesirable Interactions between the added nutraceutical and other components in the food or its environment can be avoided and the site of release of the added component can be manipulated. The appropriate application of microencapsulation technology enables the fortification of food without affecting the taste, aroma or texture of food. It can afford protection to sensitive food ingredients and enhance the shelf-life and stability of fortified foods (Brazel, C.S. (1999) Microencapsulation: offering solutions for the food industry. Cereal Foods World 44(6): 388-393; Augustin, M.A., Sanguansri, L., Margetts, C. and Young. B. (2001) Microencapsulation of food ingredients. Food Australia 53 220-223).
Microencapsulation can serve both the purposes of the food and health industries, as it is a key technology with potential for the delivery of dietary bioactives and development of successful marketable functional foods. Addressing this challenge, requires tailoring the performance of food grade microcapsules in a food processing environment so that essential sensitive components are protected during food manufacture and the microcapsules can also meet the need for site specific delivery within the gastrointestinal tract.
Directing nutraceuticals and therapeutics of the colon is of interest for treatment of colon diseases (Rubinstein, A., Tirosh, B., Baluom, M., Nassar, T., David, A., Radai, R., Gliko-Kabir, I. And Friedman, M. (1997). The rationale for peptide drug delivery to the colon and the potential for polymeric carriers as effective tools. J.
Controlled Release 46, 59-73). Targeting to colon has been carried out by formation of pro-drugs which are enzymatically cleaved in the colon, and multi-coats with pH sensitive and pressure dependent release. Often enteric acrylic polymers are used to protect cores in colon-delivery formulations.
Biopolymers, particularly polysaccharides, may be used for targeting cores to the colon where the release of cores is triggered by the microflora in the colon. A range of polysaccharides such as chitosan, pectin, arabinoxylan, arabinogalactan, xylan, cellulose dextrans, guar gum, amylose, inulin and mixtures of these have been examined and shown to have potential as colon-delivery systems (Rubinstein, A.
(2000) Natural Polysaccharides as targeting tools of drugs to the human colon.
Drug Development Research 50, 435-439; Sinha, V.R. and Kumaria, R. (2001) Polysaccharides in colon-specific drug delivery Int. J. Pharmceutics 224, 19-38;
Vandaamme, Th.F., Lenourry, A., Charrueau, C. and Chaumeil, J.-C. (2002) The use of polysaccharides to target drugs to the colon. Carbohydrate Polymers 48, 219-231; Sinha, V.R. and Kurnaria. R. (2003) Microbially triggered drug delivery to the colon. Eur. J. Pharmaceutical Sciences 18, 3-18).
There have been a number of attempts to use biopolymers for colon delivery and for treating colonic diseases US Patent 5,952,314 discloses an enteral product comprising an oil blend with fatty acids {EPA (C20:5) and DHA(C22:6)} and a source of indigestible carbohydrate which is metabolised to short chain fatty acids in the colon. It has use for improving nutritional status and treating ulcerative colitis US5108758 discloses a glassy amylose matrix for delivery of medication to the colon US 5840860 is concerned with delivery of short chain fatty acids (SCFA) to the colon by way of a modified starch.
Japanese patent 10324642 discloses a colon delivery system for delivery of bioactives (eg peptides) comprising inner layer of chitosan and outer-layer of gastric resistant material such as wheat gliadin or zein.
US 5866619 discloses a colonic delivery system for drugs such as proteins and peptides comprising a saccharide containing polymer US 6368629 discloses a drug coated with an organic acid-soluble polymer and a saccharide for colon delivery.
Biopolymers, particularly polysaccharides, may be used for targeting cores to the colon where the release of cores is triggered by the microflora in the colon. A range of polysaccharides such as chitosan, pectin, arabinoxylan, arabinogalactan, xylan, cellulose dextrans, guar gum, amylose, inulin and mixtures of these have been examined and shown to have potential as colon-delivery systems (Rubinstein, A.
(2000) Natural Polysaccharides as targeting tools of drugs to the human colon.
Drug Development Research 50, 435-439; Sinha, V.R. and Kumaria, R. (2001) Polysaccharides in colon-specific drug delivery Int. J. Pharmceutics 224, 19-38;
Vandaamme, Th.F., Lenourry, A., Charrueau, C. and Chaumeil, J.-C. (2002) The use of polysaccharides to target drugs to the colon. Carbohydrate Polymers 48, 219-231; Sinha, V.R. and Kurnaria. R. (2003) Microbially triggered drug delivery to the colon. Eur. J. Pharmaceutical Sciences 18, 3-18).
There have been a number of attempts to use biopolymers for colon delivery and for treating colonic diseases US Patent 5,952,314 discloses an enteral product comprising an oil blend with fatty acids {EPA (C20:5) and DHA(C22:6)} and a source of indigestible carbohydrate which is metabolised to short chain fatty acids in the colon. It has use for improving nutritional status and treating ulcerative colitis US5108758 discloses a glassy amylose matrix for delivery of medication to the colon US 5840860 is concerned with delivery of short chain fatty acids (SCFA) to the colon by way of a modified starch.
Japanese patent 10324642 discloses a colon delivery system for delivery of bioactives (eg peptides) comprising inner layer of chitosan and outer-layer of gastric resistant material such as wheat gliadin or zein.
US 5866619 discloses a colonic delivery system for drugs such as proteins and peptides comprising a saccharide containing polymer US 6368629 discloses a drug coated with an organic acid-soluble polymer and a saccharide for colon delivery.
US 544054 discloses a method of treating colitis with a composition containing oil blend (with DHA/EPA) and a source of indigestible carbohydrate (CHO) which is metabolised to short chain fatty acids.
US 5952314 is concerned with an enteral nutritional product for treatment of colitis which comprises oil containing EPA/DHA and a source of indigestible carbohydrate which is metabolised to short chain fatty acids.
US 6531152 describes a drug delivery system containing a water soluble core (Ca pectinate or other water-insoluble polymers) and outer coat which bursts (eg hydrophobic polymer - Eudragrit) for delivery of enterally-administered drugs to specific locations along the gastrointestinal tract There are proposals using combinations of proteins and polysaccharides for the formation of coating systems.
US 6234464 discloses a system in which oils / polyunsaturated fatty acids (PUFA)/
fatty acids are provided with capsules comprised of two layers in which the inner layer consists of gelatin, casein or alginate and the outer layer consists of gelatin, gum arabic, chitosan to provide a product stable in boiling water US 6403130 discloses a coating composition comprising a polymer containing casein and high methoxy pectin (amide formed by reaction of ester group R'COOCH3 of pectin with free amino group of protein R"NH2) WO 01/74175 discloses the encapsulation of oxygen sensitive materials such as polyunsaturated oils in a protein carbohydrate film treated to form a Maillard reaction product.
It is an object of this invention to provide a gastrointestinal delivery system that can be used with storage unstable ingredients as well as providing protection during delivery through the gut.
Brief description of the invention To this end the present invention provides a micro encapsulation material for use with storage unstable, therapeutic and nutritional agents which release the therapeutic and nutritional agents in predetermined locations in the gastro intestinal tract in which the microencapsulation material is formed by combining a food grade treated carbohydrate with a water soluble food grade protein.
US 5952314 is concerned with an enteral nutritional product for treatment of colitis which comprises oil containing EPA/DHA and a source of indigestible carbohydrate which is metabolised to short chain fatty acids.
US 6531152 describes a drug delivery system containing a water soluble core (Ca pectinate or other water-insoluble polymers) and outer coat which bursts (eg hydrophobic polymer - Eudragrit) for delivery of enterally-administered drugs to specific locations along the gastrointestinal tract There are proposals using combinations of proteins and polysaccharides for the formation of coating systems.
US 6234464 discloses a system in which oils / polyunsaturated fatty acids (PUFA)/
fatty acids are provided with capsules comprised of two layers in which the inner layer consists of gelatin, casein or alginate and the outer layer consists of gelatin, gum arabic, chitosan to provide a product stable in boiling water US 6403130 discloses a coating composition comprising a polymer containing casein and high methoxy pectin (amide formed by reaction of ester group R'COOCH3 of pectin with free amino group of protein R"NH2) WO 01/74175 discloses the encapsulation of oxygen sensitive materials such as polyunsaturated oils in a protein carbohydrate film treated to form a Maillard reaction product.
It is an object of this invention to provide a gastrointestinal delivery system that can be used with storage unstable ingredients as well as providing protection during delivery through the gut.
Brief description of the invention To this end the present invention provides a micro encapsulation material for use with storage unstable, therapeutic and nutritional agents which release the therapeutic and nutritional agents in predetermined locations in the gastro intestinal tract in which the microencapsulation material is formed by combining a food grade treated carbohydrate with a water soluble food grade protein.
The therapeutic and nutritional agents form an oil phase which is emulsified with the water dispersed or dissolved encapsulant to encapsulate the therapeutic and nutritional agents. These agents may be oils or oil soluble or oil dispersible which in the latter case may include water soluble ingredients.
The agents that may be encapsulated include lipids (oils including oxygen sensitive oils, fatty acids, triglycerides) and oil soluble and oil dispersible ingredients (including pharmaceuticals, probiotics, and bioactives). Water dispersible components including those that partition between oil and water phases may also be encapsulated. When water dispersible therapeutic and nutritional agents are used they may not be encapsulated with the oil phase but may be dispersed in the encapsulant film. The emulsions may be used as food ingredients or therapeutic agents but preferably the emulsions are dried to form powders.
Prior art encapsulation systems did not consider the use of combinations of proteins with other biopolymers for formation of capsules for target delivery of sensitive cores to the colon.
The delivery systems of this invention enable pharmaceutical and food manufacturers to offer a range of nutritionally and physiologically functional food ingredients and bioactive compounds in convenient formats and using all natural ingredients which will also enable the delivery of these products to the colon.
Some of the encapsulants used for colon delivery in this invention have the added benefits of being effective matrices for encapsulating oxygen sensitive ingredients.
The film-forming and anti-oxidant properties of some of the encapsulants used work synergistically to preserve sensitive ingredients such as polyunsaturated fatty acids from being oxidised during storage and also protects them during exposure to high temperature, pressure and moisture encountered during the processing of foods. In addition, this invention uses readily available proteins and carbohydrates.
There are no solvents used in the preparation of the encapsulated formulations as the process is an all-aqueous based system. The processes can be easily incorporated or adapted to suit most food and pharmaceutical manufacturing plants with drying operations.
The protein used may include any film forming water soluble protein or hydrolysed protein and includes milk proteins such as casein and its derivatives or whey proteins. The carbohydrate component may be those containing reducing sugar groups, oligosaccharides and starches (raw, modified, resistant, acetylated, proprionated and butylated starches).
The proteins and carbohydrates may be reacted in aqueous solutions to obtain 5 conjugates. The reaction, which occurs, can be between free amine groups of amino acids in the protein and reducing sugar groups in the carbohydrate. This type of reaction is generally termed a Maillard reaction typically occurring in the non-enzymatic browning of foods. This reaction occurs during heat processing of foods and has previously been shown to be beneficial for engineering desirable encapsulating properties for protection of oxygen sensitive components. For example, microencapsulated formulations containing oxygen sensitive oils are protected against oxidation as the Maillard reaction products [MRP] in the encapsulating matrix are good film-formers and also exhibit anti-oxidation activity as disclosed in WO 01/74175.
The starches used in the formulations may also be pre-processed using conventional and emerging processing technologies to modify the starch properties to provide improved processing characteristics during the preparation of the delivery systems. The pretreatments are chosen to break down the long starch molecules so that they form more stable emulsions and also to provide a larger number of terminal sugar reducing groups for Maillard reaction with the protein component of the encapsulant.
Colon delivery systems may be used for range of bioactives (e.g. oils), pharmaceuticals and therapeutics, which are unstable in the upper gastrointestinal tract. The protection afforded to the encapsulated components by the encapsulating material enable target release in the colon where the release is achieved after the encapsulant is degraded (e.g. by the action of microbial enzymes in the colon). Delivery of bioactives, pharmaceuticals and therapeutic components to the colon is desirable for treatment and prevention of diseases of the colon such as colorectal cancer, ulcerative colitis and inflammatory bowel disorder.
In some cases the encapsulants used in the formulations such as selected polysaccharides, can also serve as gut wall adherents or as prebiotics that facilitate growth of beneficial bacteria, and can offer added advantages. For b example delivery systems containing resistant starch have potential benefits on colonic health.
Detailed Description of the invention A number of formulations will be described, some according to the invention and some for comparative purposes to show that some formulations are suitable to delivery to the colon whilst others could be more suitable for release in the small intestine. These formulations demonstrate that the core is protected from digestion in the stomach and the environment in the small intestine.
Figures 1 to 19 of the drawings graphically illustrate the solvent extractable fat content and other properties of the formulations of the Invention as illustrated in examples I to 19 below.
The process of microencapsulating the active component involves the following manufacturing steps:
(a) Selection of the biologically active core (e.g. oil, oil soluble or oil dispersible material, bioactives, therapeutics, pharmaceuticals) (b) Dispersion of the protein and carbohydrates (or starch that has been pre-processed by conventional means such as heating or extrusion or by the use of emerging processing technologies such as high pressure processing, microfluidisation or ultrasonics) in the aqueous phase and treatment of the mixture. If desired, the protein-carbohydrate blends may be further heat processed to induce the formation of conjugates (e.g. Maillard reaction products) (c) Mixing the core with the encapsulant (i.e. protein-carbohydrate mixture) and homogenizing the mixture to obtain an emulsion, in which the core is surrounded by the encapsulant.
(d) Optionally, spray drying the emulsion to obtain a powdered formulation in which the core is surrounded by the encapsulating matrix 6a In one particular embodiment, there is provided a method of preparing microcapsules for use in storing storage unstable, therapeutic and nutritional agents for targeted delivery to predetermined locations in the gastrointestinal tract which includes the steps of:
a) selecting a nutritional or therapeutic oil, oil soluble or oil dispersible nutritional or therapeutic agent to form an oil phase b) dispersing a water soluble film forming protein and a treated resistant starch in the aqueous phase c) mixing component (a) with component (b) and homogenizing the mixture to obtain an oil-in-water emulsion d) optionally drying the emulsion to obtain a powdered formulation in which the nutritional or therapeutic oil or agent is surrounded by the component (b) thereby encapsulating the storage unstable, therapeutic or nutritional agent.
In another embodiment there is provided an encapsulation material for use with storage unstable, therapeutic and nutritional agents which releases the therapeutic and nutritional agents in predetermined locations in the gastrointestinal tract and in which the encapsulation material is formed by combining a food grade treated resistant starch with a water soluble food grade protein.
The invention further provides an orally administrable nutritional or therapeutic product for delivery of a nutritional or therapeutic agent to the gastrointestinal tract in which the agent comprises an oil or an oil soluble or dispersible component which is encapsulated in a material as described herein.
Emulsion formulations Tuna fish oil was used as an oil of choice in most of these examples since it contains a high amount of long chain polyunsaturated fatty acids and this needs to be protected from oxidation prior to consumption. In addition there is interest in delivering these to the colon because of their potential for prevention of colorectal cancer and promotion of bowel health (Karmeli, R A. (1996) Historical Perspective and Potential Use of n-3 Fatty Acids in Therapy of Cancer Cachia. Nutrition, Vol 12 (1) S2-S4; Dommels Y E M, Alink, G M, van Bladeren, P J, van Ommen, B (2002) Dietary n-6 and n-3 polyunsaturated fatty acids and colorectal carcinogenesis:
results from cultured colon cells, animal models and human studies, Environmental Toxicology and Pharmacology, Vol 12 (4), 233-244.). Tributyrin and lutein were also included as examples. The encapsulation of probiotics (i.e. an example of a water dispersible component) using this technology has been previously disclosed in WO 01174175.
A range of formulations was prepared using protein and/or carbohydrate (raw or pre-processed) and oil mixtures at different ratios. The formulations were made-up to contain 25 and 50% fat In the final powder:
The protein used in these examples were sodium caseinate, whey protein isolate and hydrolysed milk proteins. The carbohydrates used, alone or in combination, were glucose, oligosaccharides, dried glucose syrup, modified starches, resistant starches and native starches. Polysaccharides, including high-methoxy pectin, alginate, carrageenan, guar gum, were added to protein-carbohydrate mixtures in some formulations.
Manufacture of microcapsules Materials The core materials used in the examples include: tuna oil, tributyrin and 15%
(w/w) lutein (mostly as dipalmitate and dimyristate lutein esters) in soy bean oil.
Proteins used as encapsulant in the examples include: sodium caseinate (NaCas), whey protein isolate (WPI), hydrolysed casein protein (HCP) and hydrolysed whey protein (HWP).
Carbohydrates used in the examples include: dextrose monohydrate (Glu), waxy maize, maize starch, dried glucose syrup (DGS), wheat starch, oligofructose (oligo), tapioca dextrin (K4484), modified starch (CapsulT"'), modified starch (Hi-CapTM 100), Hi-MaizeTM, HylonTM VII, NoveloseTM 260 and Novelose 330, potato starch, sodium alginate, kappa carrageenan, high methoxy pectin (HMP) and guar gum.
Preparation of protein-carbohydrate encapsulants In some cases, unreacted blends of protein and carbohydrates (referred to as NonMRP formulations since these were not heated to induce the formation of Maillard reaction products) were used as the encapsulating matrix. For the preparation of reacted protein-carbohydrate encapsulants (referred to as MRP
formulations as these were heated to induce the formation of Maillard reaction products), protein was dissolved in 60 C water, using a high shear mixer, and then the sugars, starch or the selected carbohydrate were added. Where a polysaccharide was also added, the polysaccharide was first allowed to hydrate in water at 90 C temperature before addition into the protein-sugar mixture. The pH
of the protein-sugar/starch /gum mixtures was adjusted to 7.5. The mixture were then filled into 3 litre cans, sealed and heated in the retort to 98 C and held for 30 minutes, then cooled down to room temperature. Microcapsule formulations are given in the examples below together with the methods used for the manufacture of microcapsules.
Preparation of protein-starch encapsulants Protein was dissolved in 60 C water to make 15% total solids (TS) solution, using a high shear mixer. Starch (raw or heated, heated and microfluidised, extruded, high pressure processed and ultrasonicated) was prepared and processed separately to make a 10% TS solutions or dispersions in 70 C water (See Preparation of Starches for Microencapsulation detailed below). The 15%TS
protein solution were mixed together with the 10%TS starch to get a 12%TS
mixture with a 1:1 protein:starch ratio. Where MRP was required, the mixture were then filled into 3 litre cans, sealed and heated in the retort to 98 C and held for 30 minutes, then cooled down to 60 C.
Preparation of Starches for Microencapsulation Raw or Unprocessed 10% TS starch dispersion (no pre-treatment applied) was mixed with 15% TS of protein solution at 60 C.
Heat processing 20% TS of each starch dispersion (except for potato starch where a 10% TS
dispersion was used due to high viscosity at 20% TS) were heated at 121 C for minutes in a 73x82 mm cans. Once heat processed, 70 C deionised water was added to dilute the sample to 10% TS in a high shear mixer. This heat processed starch was mixed with 15% TS of protein solution at 60 C. This mixture was then used for microencapsulation of bioactives.
Heat processing and Micro fluidisation treatment 20% TS of each starch dispersion (except for potato starch where a 10% TS
dispersion was used due to high viscosity at 20% TS) were heated at 121 C for minutes in a 73x82 mm cans. Once heat processed, 70 C deionised water was added to dilute the sample to 10% TS in a high shear mixer, and processed at 60 C through a pilot scale M-210B EH microfluidiser (MFIC, Newton MA, USA).
The plant was operated at 800 bars and 3 passes using a combination of 425 pm Q50Z auxiliary processing module and 200 pm E230Z interaction chamber (for dispersion and cell disruption). The microfluidised (MF) starch was mixed with 15% TS of protein solution at 60 C for microencapsulation.
Heat processing and Ultra-high pressure treatment 20% TS of a starch dispersion was heated at 121 C for 60 minutes ina 73x82 mm cans. Once heat processed, 70 C deionised water was added to dilute the sample to 10% TS in a high shear mixer, and processed by ultra-high pressure treatment at 6,000 bars for 15 minutes using HPP-QFP 35L unit. The ultra-high pressure treated (HPP) starch was mixed with 15% TS of protein solution at 60 C for microencapsulation.
Heat processing and Ultrasonics treatment 20% TS of a starch dispersion was heated at 121 C for 60 minutes in 73x82 mm cans. Once heat processed, 70 C deionised water was added to dilute the sample to 10% in a high shear mixer, and processed with ultrasound treatment at 50 ml/min @ 380 watts using 20KHz unit. The ultrasound treated (US) starch was mixed with 15% TS of protein solution at 60 C for microencapsulation.
Extrusion Resistant starches were processed using a twin-screw extruder (model MPF 40, APV Baker, Peterborough PE3-6TA, England) 40mm screw diameter and length,to diameter ratio of 25:1, and a low shear screw configuration. A 4 mm die was used throughout the trial. Raw materials were fed into feed port 1 at 15 kg h-' for resistant starch processing using a gravimetric feeder (Ktron Soder AG CH-5702, Niederlenz) and water was injected into port 2 with a volumetric pump (Brook Crompton, Huddersfield, England). Barrel moisture was injected at 20-40 % and the die melt temperature was varied from 140 to 178 C with increasing screw speed from 150-250rpm. The extruded resistant starches were milled to 0.2mm particle size powder. 10% TS extruded starch dispersion was mixed with 15% TS
5 of protein solution at 60 C for microencapsulation.
Preparation of oil in water emulsions The protein-carbohydrate mixtures and the tuna oil were pre-heated to 60 C
separately. The bioactive core was added into the protein-carbohydrate mixture using a Silverson high shear mixer. The mixture were then homogenised at 350 10 and 100 bar pressures in two stages using a Rannie homogeniser.
Spray drying of emulsions The homogenised emulsions were spray dried at 50-60 C feed temperature, 180 C inlet temperature and 80 C outlet temperature using a Niro production minor spray dryer. The powder was collected from the main chamber and packed.
Estimation of solvent extractable fat in tuna oil powders The estimation of solvent-extractable was based on the method by Pisecky (Handbook of Milk Powder Manufacture, 1997) except that petroleum ether was used in place of carbon tetrachloride. Fifty ml of petroleum ether (b.p. 40-60 C) was added to 10g powder. The mixture was agitated in a stoppered flask for 15 minutes. The mixture was filtered and the solvent evaporated at 60 C using a rotary evaporator. The remaining fat residue was then dried in an oven at 105 C
for 1 h.
In-vitro testing of microcapsules The stability of the microcapsules in the stomach and the small-intestine was u estimated by assessment of oil-release properties of microcapsules (a) incubated in simulated gastric fluid (SGF) (pH 1.2) for 2h at 37 C and 100 rpm in a shaker water-bath incubator and (b) incubated in SGF (2 h at 37 C and 100 rpm in a shaker water-bath incubator) followed by exposure to simulated intestinal fluid (SIF) (pH 6.8) (3 h at 37 C and 100 rpm). SGF and SIF were prepared according to the methods given in the US Pharmacopeia (US Pharmacopeia 2000 &
National Formulatory (USP 24 NF 19), Rockville, MD) For estimation of released oil from microcapsules in-vitro:
The solvent extractable fat from the incubated samples were measured. The sample was transferred into a 250 ml stoppered separating funnel and extracted with petroleum ether (75 ml plus 2x25m1). The sample was filtered through a phase separation filter paper to obtain. the solvent phase after each extraction.
The solvent was removed to recover the oil released.
For estimation of released lutein in-vitro:
The microcapsule containing the lutein (1.0 g) was incubated sequentially with SGF (pH 1.2) and SIF (pH6.8) as outlined above. For estimation of released lutein, the solvent extractable lutein from the incubated samples was measured.
The extraction was performed in a centrifuge tube. The sample was extracted with petroleum ether (15 ml plus 2xlOml). The sample was centrifuged (2000 rpm for 10 min) after each extraction and the top solvent layer removed. The combined solvent extracts were filtered through a phase separation filter paper prior to dilution with petroleum ether. The absorbance of the diluted extract was measured at 444 nm and the concentration of extracted lutein was determined.
For estimation of released Tributyrin in-vitro:
The microcapsule containing the tributyrin (1.0 g) was incubated sequentially with SGF (pH 1.2) and SIF (pH 6.8) as outlined above. For estimation of released tributyrin samples that were exposed to SGF only were used directly and that exposed sequentially to SGF and SIF was adjusted to pH 2. To this mixture was added 2.5 g NaCl and 15 ml dichloromethane and the mixture was centrifuged at 2500 rpm for 10 min at 5 C. The aqueous layer was removed and kept while the dichloromethane layer was decanted into a conical flask without disturbing the gelatinous precipitate floating on top of the dichloromethane layer. The aqueous layer with the gelatinous precipitate was extracted with another 15 ml dichloromethane. The dichloromethane extracts were dried over anhydrous Na2SO4, before filtering (0.45 pm PTFE syringe filter). The dichloromethane was removed under Nitrogen in a warm water bath. The extracted material was dissolved in 10 ml hexane/iso-propyl alcohol (99:1, v/v) and the solution stored in freezer. The amount of tributyrin and butyric acid in the extract was analysed by normal-phase HPLC. [Column: PVA-Sil guard and analytical (250mm x 4.6 mm I.D.) columns; UV detector (210 nm)].
In-vivo testing of microcapsules Male Sprague-Dawley rats, approximately 10 weeks of age were used for the in-vivo study. Rats were denied solid food for 24 hours prior to dosing, but were allowed free access to drinking water containing 2.5% glucose, 0.5% NaCl and 0.005% KCI (all w/v).
Preparation of radiolabelled tuna oil: 0.5 ml or 25 pCi radiolabelled tracer [1-14C]
18:3 ([14C] trilinolenin, 50-60 mCi/mmol; 50 pCi/mL) was added to 4.56 g tuna oil.
Two lots of tuna oil samples with radiolabelled trilinolenin were prepared, one for encapsulated oil treatment (see example 19 for formulation and manufacture) and one for free (unencapsulated) oil treatment.
Rat treatment: On the day of treatment rats were fed intra-gastrically using a stainless steel gavage needle either with 0.3 ml fish oil mixed with radiolabelled tracer [14C] 18:3 (0.27 g tuna oil + 0.03 ml tracer [14C] 18:3) for control treatment or 2 ml emulsion (0.09 g tuna oil + 0.01 ml tracer [14C] 18:3) for the microencapsulated treatment.
Tissue sampling: At time points of 4, 9 and 14 hours following treatment, rats were anesthetised and a blood sample taken by cardiac puncture. The stomach, small intestine, caecum and colon were removed. The small intestine was divided into two sections, each GI tract segment was flushed with 0.9% NaCl and the washings collected and frozen. The GI tract segments were then frozen for subsequent analysis. Faeces were also collected for analysis at time points. The tissues and faeces were weighed and samples taken for analysis and weighed.
Tissue sample analysis: Radioactivity of GI tract washings containing all unabsorbed oil (both released and encapsulated oil) was counted to estimate the total amount of radioactivity. Tissue samples were dissolved overnight in BTS-450R tissue solubiliser. Faecal matters were dissolved in BTS-4508, with some prior treatment. The liquid scintillation cocktail Ready Organic R was added to each sample and the sample subjected to liquid scintillation counting in a Packard 1500 Tri-Carb Scintillation Counter.
Example 1: Formulations and Manufacture of Powders with 25% oil loading with unheated or heated blends of protein-glucose/dried glucose syrup or protein-oligosaccharide as encapsulants Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare NaCas solution (Alanate) at 60 C, add Alanate 180 25.0% 7.7% sugars [glucose and DGS (Maltostar)], Glucose.H20 25.0% 7.7% (preferably, adjust pH of solution to 7.5, heat to Maltostar 30 25.0% 7.7% 98 C and hold for 30 minutes, cool down to Tuna oil 25.0% 7.7% 60 C), add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Inlet Total 100.0% 100.0% temperature Ti /Outlet temperature (To).
Ingredient powder Emulsion Processing steps composition compositio Water 69.2% Prepare NaCas solution at 60 C, add Alanate 180 25.0% 7.7% oligosaccharide, (preferably, adjust pH of Raftilose P95 50.0% 15.4% solution to 7.5, heat to 98 C and hold for 30 Tuna oil 25.0% 7.7% minutes, cool down to 60 C), add oil heated to 60 C, homogenise at 350/100 bar, spray dry at Total 100.0% 100.0% 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare WPI solution (Alacen) at 60 C, add Alacen 895 25.0% 7.7% sugars, (preferably, adjust pH of solution to 7.5, Glucose.H20 25.0% 7.7% heat to 98 C and hold for 30 minutes, cool down Maltostar 30 25.0% 7.7% to 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 7.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare WPI solution at 60 C, add Alacen 895 25.0% 7.7% oligosaccharidesugars, (preferably, adjust pH of Raftilose P95 50.0% 15.4% solution to 7.5, heat to 98 C and hold for 30 Tuna oil 25.0% 7.7% minutes, cool down to 60 C), add oil heated to Total 100.0% 100.0% 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 2: Formulations and Manufacture of Powders with 50% oil loading with unheated or heated blends of protein- glucose/dried glucose syrup or protein-oligosaccharide as encapsulants Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare NaCas solution at 60 C, add sugars, Alanate 180 16.7% 6.7% (preferably, adjust pH of solution to 7.5, heat to Glucose.H20 16.7% 6.7% 98 C and hold for 30 minutes, cool down to Maltostar 30 16.7% 6.7% 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 20.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare NaCas solution at 60 C, add Alanate 180 16.7% 6.7% oligosaccharide (Raftilose), (preferably, adjust pH
Raftilose P95 33.3% 13.3% of solution to 7.5, heat to 98 C and hold for 30 Tuna oil 50.0% 20.0% minutes, cool down to 60 C), add oil heated to Total 100.0% 100.0% 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare WPI solution at 60 C, add sugars, Alacen 895 16.7% 6.7% (preferably, adjust pH of solution to 7.5, heat to Glucose.H20 16.7% 6.7% 98 C and hold for 30 minutes, cool down to Maltostar 30 16.7% 6.7% 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 20.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare WPI solution at 60 C, add Alacen 895 16.7.0% 6.7% oligosaccharidesugars, (preferably, adjust pH of Raftilose P95 33.3% 13.3% solution to 7.5, heat to 98 C and hold for 30 Tuna oil 50.0% 20.0% minutes, cool down to 60 C), add oil heated to 60 C, homogenise at 350/100 bar, spray dry at Total 100.0% 100.0% 180/80 C Ti/To.
Example 3: Formulations and Manufacture of Powders with 25% oil loading with heated blends of protein- starch as encapsulants Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare NaCas solution at 60 C, add starch Alanate 180 25.0% 7.7% (Capsul), (preferably, adjust pH of solution to 7.5, Capsul 50.0% 15.4% heat to 98 C and hold for 30 minutes, cool down Tuna oil 25.0% 7.7% to 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare NaCas solution at 60 C, add starch (Hi-Alanate 180 25.0% 7.7% Cap), (preferably, adjust pH of solution to 7.5, Hi-Cap 100 50.0% 15.4% heat to 98 C and hold for 30 minutes, cool down Tuna oil 25.0% 7.7% to 60 C), add oil heated to 60 C, homogenise at Total ~---100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare NaCas solution at 60 C, add dextrin, Alanate 180 25.0% 7.7% (preferably, adjust pH of solution to 7.5, heat to Tapioca dextrin 50.0% 15.4% 98 C and hold for 30 minutes, cool down to K4484 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 7.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare WPI solution at 60 C, add dextrin, Alacen 895 25.0% 7.7% (preferably, adjust pH of solution to 7.5, heat to Tapioca dextrin 50.0% 15.4% 98 C and hold for 30 minutes, cool down to K4484 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 7.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Example 4: Formulations and Manufacture of Powders with 50% oil loading with 5 heated blends of protein- starch as encapsulants Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare NaCas solution at 60 C, add starch, Alanate 180 16.7% 6.7% (preferably, adjust pH of solution to 7.5, heat to Capsul 33.3% 13.3% 98 C and hold for 30 minutes, cool down to Tuna oil 50.0% 20.0% 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare NaCas solution at 60 C, add starch, Alanate 180 16.7% 6.7% (preferably, adjust pH of solution to 7.5, heat to Hi-Cap 100 33.3% 13.3% 98 C and hold for 30 minutes, cool down to Tuna oil 50.0% 20.0% 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare NaCas solution at 60 C, add dextrin, Alanate 180 16.7% 6.7% (preferably, adjust pH of solution to 7.5, heat to Tapioca dextrin 33.3% 13.3% 98 C and hold for 30 minutes, cool down to K4484 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 20.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare WPI solution at 60 C, add dextrin, Alacen 895 16.7% 6.7% (preferably, adjust pH of solution to 7.5, heat to Tapioca dextrin 33.3% 13.3% 98 C and hold for 30 minutes, cool down to K4484 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 20.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Example 5: Formulations and Manufacture of Powders with 25% oil loading with heated blends of protein-glucose/glucose syrup or protein-oligosaccharide in combination with gums as encapsulants Ingredient powder emulsion Processing steps composition com osition Water 69.2% Prepare NaCas solution at 60 C, add sugars and Alanate 180 25.0% 7.7% alginate (Protanal), (preferably, adjust pH of Glucose.H20 25.0% 7.7% solution to 7.5, heat to 98 C and hold for 30 Maltostar 30 22.5% 6.9% minutes, cool down to 60 C), add oil heated to Protanal 2.5% 0.8% 60 C, homogenise at 350/100 bar, spray dry at Tuna oil 25.0% 7.7% 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 77.7% Prepare NaCas solution at 60 C, add Alanate 180 25.0% 5.6% oligosaccharide and guar gum solution, Raftilose P95 48.75% 10.9% (preferably, adjust pH of solution to 7.5, heat to Guar 1.25% 0.3% 98 C and hold for 30 minutes, cool down to WW250F 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 5.6% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 73.2% Prepare NaCas solution at 60 C, add Alanate 180 25.0% 6.7% oligosaccharide and carrageenan solution Raftilose P95 48.75% 13.0% (Gelcarin), (preferably, adjust pH of solution to Gelcarin 1.25% 0.3% 7.5, heat to 98 C and hold for 30 minutes, cool GP 812 down to 60 C), add oil heated to 60 C, Tuna oil 25.0% 6.7% homogenise at 350/100 bar, spray dry at Total 100.0% 100.0% 180/80 C Ti/To.
Ingredient powder emulsion Processing steps com osition composition Water 73.1% Prepare NaCas solution at 60 C, add Alanate 180 25.0% 6.7% oligosaccharide and high methoxy pectin (HMP) Raftilose P95 47.5% 12.7% solution, (preferably, adjust pH of solution to 7.5, HMP RS400 2.5% 0.7% heat to 98 C and hold for 30 minutes, cool down Tuna oil 25.0% 6.7% to 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 73.1% Prepare NaCas solution at 60 C, add glucose-Alacen 895 25.0% 6.7% DGS and high methoxy pectin (HMP) solution, 1:1 GIu:DGS 47.5% 12.7% (preferably, adjust pH of solution to 7.5, heat to HMP RS400 2.5% 0.7% 98 C and hold for 30 minutes, cool down to Tuna oil 25.0% 6.7% 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition compositio Water 77.7% Prepare WPI solution at 60 C, add Alacen 895 25.0% 5.6% oligosaccharide and guar gum solution, Raftilose P95 48.75% 10.9% (preferably, adjust pH of solution to 7.5, heat to Guar 1.25% 0.3% 98 C and hold for 30 minutes, cool down to WW250F 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 5.6% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 73.2% Prepare NaCas solution at 60 C, add Alacen 895 25.0% 6.7% oligosaccharide and 60 C carrageenan solution, Raftilose P95 48.75% 13.0% (preferably, adjust pH of solution to 7.5, heat to Gelcarin 1.25% 0.3% 98 C and hold for 30 minutes, cool down to GP 812 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 6.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition water 73.1% Prepare NaCas solution at 60 C, add Alacen 895 25.0% 6.7% oligosaccharide and 60 C HMP solution, Raftilose P95 47.5% 12.7% (preferably, adjust pH of solution to 7.5, heat to HMP RS400 2.5% 0.7% 98 C and hold for 30 minutes, cool down to Tuna oil 25.0% 6.7% 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Example 6: Formulations and Manufacture of Powders with 50% oil loading with heated blends of protein-glucose/glucose cose/glucose syrup or protein-oligosaccharide in combination with gums as encapsulants Ingredient powder emulsion Processing steps composition composition water 60.0% Prepare NaCas solution at 60 C, add sugars and Alanate 180 16.7% 6.7% alginate, (preferably, adjust pH of solution to 7.5, Glucose 16.7% 67% heat to 98 C and hold for 30 minutes, cool down Maltostar 30 15.0% 6.0% to 60 C), add oil heated to 60 C, homogenise at Protanal 1.7% 0.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Tuna oil 50.0% 20.0%
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 69.9% Prepare HWP solution at 60 C, add NaCas 16.7% 5.0% oligosaccharide and guar gum solution, Raftilose P95 32.5% 9.8% (preferably, adjust pH of solution to 7.5, heat to Guar 0.8% 0.3% 98 C and hold for 30 minutes, cool down to WW250F 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 15.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 64.6% Prepare NaCas solution at 60 C, add Alanate 180 16.7% 5.9% oligosaccharide and carrageenan solution, Raftilose P95 32.5% 11.5% (preferably, adjust pH of solution to 7.5, heat to Gelcarin 0.8% 0.3% 98 C and hold for 30 minutes, cool down to GP 812 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 17.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 64.5% Prepare NaCas solution at 60 C, add Alanate 180 16.7% 5.9% oligosaccharidesugars and HMP solution, Raftilose P95 31.7% 11.2% (preferably, adjust pH of solution to 7.5, heat to HMP RS400 1.7% 0.6% 98 C and hold for 30 minutes, cool down to Tuna oil 50.0% 17.8% 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 69.9% Prepare WPI solution at 60 C, add Alacen 895 16.7% 5.0% oligosaccharide and guar gum solution, Raftilose P95 32.5% 9.8% (preferably, adjust pH of solution to 7.5, heat to Guar 0.8% 0.3% 98 C and hold for 30 minutes, cool down to WW250F 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 15.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 53.1% Prepare WPI solution at 60 C, add Alacen 895 16.7% 5.9% oligosaccharide and carrageenan solution, Raftilose P95 32.5% 11.5% (preferably, adjust pH of solution to 7.5, heat to Gelcarin 0.8% 0.3% 98 C and hold for 30 minutes, cool down to GP 812 60 C), add oil heated to 60 C, homogenise at Water for gum 11.5% 350/100 bar, spray dry at 180/80 C Ti/To.
dispersion Tuna oil 50.0% 17.7%
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 53.3% Prepare WPI solution at 60 C, add Alacen 895 16.7% 5.9% oligosaccharide and 60 C HMP solution, Raftilose P95 31.7% 11.2% (preferably, adjust pH of solution to 7.5, heat to HMP RS400 1.7% 0.6% 98 C and hold for 30 minutes, cool down to Water for gum 11.2% 60 C), add oil heated to 60 C, homogenise at dispersion 350/100 bar, spray dry at 180/80 C Ti/To.
Tuna oil 50.0% 17.8%
Total 100.0% 100.0%
Example 7: Formulations and Manufacture of Powders with 25% oil loading with heated blends of protein hydrolysate - oligosaccharide in combination with gums as encapsulants Ingredient powder emulsion Processing steps composition composition Water 73.2% Prepare hydrolysed casein protein (HCP) HCP 102 25.0% 6.7% solution at 60 C, add oligosaccharide, and 60 C
Raftilose P95 48.75% 13.0% carrageenan solution (preferably, adjust pH of Gelcarin 1.25% 0.3% solution to 7.5, heat to 98 C and hold for 30 GP 812 minutes, cool down to 60 C), add oil heated to Tuna oil 25.0% 6.7% 60 C, homogenise at 350/100 bar, spray dry at Total 100.0% 100.0% 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 73.1% Prepare HCP solution at 60 C, add HCP 102 25.0% 6.7% oligosaccharide and HMP solution, (preferably, Raftilose P95 47.5% 12.7% adjust pH of solution to 7.5, heat to 98 C and HMP RS400 2.5% 0.7% hold for 30 minutes, cool down to 60 C), add of 1 Tuna oil 25.0% 6.7% heated to 60 C, homogenise at 350/100 bar, Total 100.0% 100.0% spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 73.2% Prepare hydrolysed whey protein (HWP) solution HWP 205 25.0% 6.7% at 60 C, add oligosaccharide and carrageenan Raftilose P95 48.75% 13.0% solution, (preferably, adjust pH of solution to 7.5, Gelcarin 1.25% 0.3% heat to 98 C and hold for 30 minutes, cool down GP 812 to 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 6.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 73.1% Prepare HWP solution at 60 C, add HWP 205 25.0% 6.7% oligosaccharide and HMP solution, (preferably, Raftilose P95 47.5% 12.7% adjust pH of solution to 7.5, heat to 98 C and HMP RS400 2.5% 0.7% ' hold for 30 minutes, cool down to 60 C), add oil Tuna oil 25.0% 6.7% heated to 60 C, homogenise at 350/100 bar, Total 100.0% 100.0% spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 73.1% Prepare HWP solution at 60 C, add glucose-HWP 205 25.0% 6.7% DGS and HMP solution, (preferably, adjust pH of 1:1 Glu:DGS 47.5% 12.7% solution to 7.5, heat to 98 C and hold for 30 HMP RS400 2.5% 0.7% minutes, cool down to 60 C), add oil heated to Tuna oil 25.0% 6.7% 60 C, homogenise at 350/100 bar, spray dry at Total 100.0% 100.0% 180/80 C Ti/To.
Example 8: Formulations and Manufacture of Powders with 50% oil loading with heated blends of hydrolysate - oligosaccharide in combination with gums as encapsulants Ingredient powder emulsion Processing steps composition composition Water 64.6% Prepare HCP solution at 60 C, add HCP 102 16.7% 5.9% oligosaccharide and carrageenan solution, Raftilose P95 32.5% 11.5% (preferably, adjust pH of solution to 7.5, heat to Gelcarin 0.8% 0.3% 98 C and hold for 30 minutes, cool down to GP 812 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 17.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 64.5% Prepare HCP solution at 60 C, add HCP 102 16.7% 5.9% oligosaccharide and HMP solution, (preferably, Raftilose P95 31.7% 11.2% adjust pH of solution to 7.5, heat to 98 C and HMP RS400 1.7% 0.6% hold for 30 minutes, cool down to 60 C), add oil Tuna oil 50.0% 17.8% heated to 60 C, homogenise at 350/100 bar, Total 100.0% 100.0% spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 64.6% Prepare HWP solution at 60 C, add HWP 205 16.7% 5.9% oligosaccharide and carrageenan solution, Raftilose P95 32.5% 11.5% (preferably, adjust pH of solution to 7.5, heat to Gelcarin 0.8% 0.3% 98 C and hold for 30 minutes, cool down to GP 812 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 17.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 64.5% Prepare HWP solution at 60 C, add HWP 205 16.7% 5.9% oligosaccharide and HMP solution, (preferably, Raftilose P95 31.7% 11.2% adjust pH of solution to 7.5, heat to 98 C and HMP RS400 1.7% 0.6% hold for 30 minutes, cool down to 60 C), add oil Tuna oil 50.0% 17,8% heated to 60 C, homogenise at 350/100 bar, Total 100.0% 100.0% spray dry at 180/80 C Ti/To.
Example 9: Formulations and Manufacture of Powders with 25% oil loading with blends of sodium caseinate with raw or processed resistant starch (potato starch) Ingredient powder emulsion Processing steps (using raw potato starch) composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Potato starch 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and mix Alanate 180 37.5% 5.8% with starch dispersion above. (Preferably heat Tuna oil 25.0% 3.8% protein-starch mixture in cans at 98 C-30 Total 100,0% 100.0% minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed potato composition composition starch Water 84.6% Prepare 10%TS starch dispersion at 70 C, Potato starch 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down. Prepare 15%TS NaCas Tuna oil 25.0% 3.8% solution at 60 C and mix with processed starch Total 100.0% 100.0% above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised potato starch) Water 84.6% Prepare 10%TS starch dispersion at 70 C, Potato starch 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, microfluidise at 800 bar-3 Tuna oil 25.0% 3.8% passes. Prepare 15%TS NaCas solution at 60 C
Total 100.0% 100.0% and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using extruded potato starch) composition composition Water 84.6% Prepare 10%TS extruded starch dispersion at Potato starch 37.5% 5.8% 70 C. Prepare 15%TS NaCas solution at 60 C
Alanate 180 37.5% 5.8% and mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in cans at Total 100.0% 100.0% 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 10: Formulations and Manufacture of Powders with 25% oil loading with blends of sodium caseinate with Hylon VII or pre-processed resistant starch (Hylon VII
Ingredient powder emulsion Processing steps (using Hylon VII starch) composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Hylon VII 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and mix Alanate 180 37.5% 5.8% with starch dispersion above. (Preferably heat Tuna oil 25.0% 3.8% protein-starch mixture in cans at 98 C-30 Total 100.0% 100.0% minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed Hylon composition composition VII starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS Prepare 15%TS NaCas Total 100.0% 100.0% solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder = emulsion Processing steps (using heat processed and composition composition microfluidised Hylon VII starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using extruded Hylon VII
composition composition starch) Water 84.6% Prepare 10%TS extruded starch dispersion at Hylon VII 37.5% 5.8% 70 C. Prepare 15%TS NaCas solution at 60 C
Alanate 180 37.5% 5.8% and mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in cans at Total 100.0% 100.0% 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 11: Formulations and Manufacture of Powders with 25% oil loading with blends of sodium caseinate with Hi-Maize 1043 or pre-processed resistant starch (Hi-Maize 1043) Ingredient powder emulsion Processing steps (using Hi-Maize starch) composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Hi-Maize 1043 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and mix Alanate 180 37.5% 5.8% with starch dispersion above. (Preferably heat Tuna oil 25.0% 3.8% protein-starch mixture in cans at 98 C-30 Total 100.0% 100.0% minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed Hi-composition composition Maize starch) Water 84.6% Prepare 20%TS starch dispersion at 60 C, Hi-Maize 1043 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS. Prepare 15%TS NaCas Total 100.0% 100.0% solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Hi-Maize starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hi-Maize 1043 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, __spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using extrude Hi-Maize starch) composition composition Water 84.6% Prepare 10%TS extruded starch dispersion at Hi-Maize 1043 37.5% 5.8% 70 C. Prepare 15%TS NaCas solution at 60 C
Alanate 180 37.5% 5.8% and mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in cans at Total 100.0% 100.0% 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dr at 180/80 C Ti/To.
Example 12: Formulations and Manufacture of Powders with 25% oil loading with blends of sodium caseinate with Novelose 260 or pre-processed resistant starch (Novelose 260) Ingredient powder emulsion Processing steps (using Novelose 260 starch) composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Novelose 260 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and mix Alanate 180 37.5% 5.8% with starch dispersion above. (Preferably heat Tuna oil 25.0% 3.8% protein-starch mixture in cans at 98 C-30 Total 100.0% 100.0% minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed composition composition Novelose 260 starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Novelose 260 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS. Prepare 15%TS NaCas Total 100.0% 100.0% solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Novelose 260 starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Novelose 260 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% IS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 84.6% Prepare 10%TS extruded starch dispersion at Novelose 260 37.5% 5.8% 70 C. Prepare 15%TS NaCas solution at 60 C
Alanate 180 37.5% 5.8% and mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in cans at Total 100.0% 100.0% 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 13: Formulations and Manufacture of Powders with 25% oil loading with blends of sodium caseinate with Novelose 330 or pre-processed resistant starch (Novelose 330) Ingredient powder emulsion Processing steps (using Novelose 330 starch) composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Novelose 330 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and mix Alanate 180 37.5% 5.8% with starch dispersion above. (Preferably heat Tuna oil 25.0% 3.8% protein-starch mixture in cans at 98 C-30 Total 100.0% 100.0% minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed composition composition Novelose 330 starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Novelose 330 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% IS. Prepare 15%TS NaCas Total 100.0% 100.0% solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Novelose 330 starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Novelose 330 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% IS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using extruded Novelose 330 starch composition composition Water 84.6% Prepare 10%TS extruded starch dispersion at Novelose 330 37.5% 5.8% 70 C. Prepare 15%TS NaCas solution at 60 C
Alanate 180 37.5% 5.8% and mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in cans at Total 100.0% 100.0% 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 14: Formulations and Manufacture of Powders with 25% oil loading with blends of sodium caseinate with Hylon VII or high pressure processed or ultrasonciated resistant starch (Nylon VII) Ingredient powder emulsion Processing steps (using Hylon VII starch) composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Hylon VII 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and mix Alanate 180 37.5% 5.8% with starch dispersion above. (Preferably heat Tuna oil 25.0% 3.8% protein-starch mixture in cans at 98 C-30 Total 100.0% 100.0% minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised x1 pass Hylon VII starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down,. add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-1 Total 100.0% 100.0% pass. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bars, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised x3 pass Hylon VII starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bars, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using extruded Hylon VII
composition composition starch) Water 84.6% Prepare 10%TS extruded starch dispersion at Hylon VII 37.5% 5.8% 70 C. Prepare 15%TS NaCas solution at 60 C
Alanate 180 37.5% 5.8% and mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in cans at Total 100.0% 100.0% 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bars, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using high pressure treated composition composition Hylon VII starch Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, HPP at 600 MPa, for 15 Total 100.0% 100.0% minutes. Prepare 15%TS NaCas solution at 60 C and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using ultrasound treated Hylon composition composition VII starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, US using 20 KHz unit @ 50 Total 100.0% 100.0% ml per minute, 380 Watts. Prepare 15%TS
NaCas solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 15: Formulations and Manufacture of Powders with 25% oil loading with unheated and heated blends of sodium caseinate with raw starches or pre-processed starch Ingredient powder emulsion Processing steps composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Waxy maize 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and Alanate 180 37.5% 5.8% mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in Total 100.0% 100.0% cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition corn osition Water 84.6% Prepare 20%TS starch dispersion at 70 C, Waxy maize 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, Microfluidise at 800 Total 100.0% 100.0% bar-1 pass. Prepare 15%TS NaCas solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Maize starch 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and Alanate 180 37.5% 5.8% mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in Total 100.0% 100.0% cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition Water 84.6% Prepare 20%TS starch dispersion at 70 C, Maize starch 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, Microfluidise at 800 bar-1 pass. Prepare 15%TS NaCas solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C) Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Wheat starch 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and Alanate 180 37.5% 5.8% mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in Total 100.0% 100.0% cans at 98 C-30 minutes, cool down to 60 C) Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 84.6% Prepare 20%TS starch dispersion at 70 C, Wheat starch 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, Microfluidise at 800 Total 100.0% 100.0% bar-1 pass. Prepare 15%TS NaCas solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C) Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 16: Formulations and Manufacture of Powders with 25% (lutein-in-oil) in heated and unheated blends of protein-sugar-starch as encapsulants Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare NaCas solution at 60 C, add DGS and Alanate 180 25.0% 7.7% starch, (preferably, adjust p-H of solution to 7.5, Maltostar 30 25.0% 7.7% heat to 98 C and hold for 34 minutes, cool down Tapioca dextrin 25.0% 7.7% to 60 C), add lutein heated to 90 C, homogenise K4484 at 350/100 bars, spray dry at 180/80 C Ti/To.
Lutein in oil 25.0% 7.7%
Total 100.0% 100.0%
Example 17: Formulations and Manufacture of Powders with 25% tributyrin in heated blends of protein-sugar or protein-sugar-RS starch as encapsulants Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare NaCas solution at 60 C, add sugars, Alanate 180 25.0% 7.7% (preferably, adjust pH of solution to 7.5, heat to Glucose 25.0% 7.7% 98 C and hold for 30 minutes, cool down to Maltostar 30 25.0% 7.7% 60 C), add tributyrin, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Tributyrin 25.0% 7.7%
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Hylon VII starch) Water 69.2% Prepare 20%TS starch dispersion at 70 C, Alanate 180 25.0% 7.7% process in 73 x 82 mm cans at 121 C-60 Glucose 25.0% 7.7% minutes, cool down, add remaining water to Hylon VII 25.0% 7.7% make-up to 10% TS, micrvfluidise at 800 bar-3 Tributyrin 25.0% 7.7% passes. Prepare 15%TS NaCas solution at Total 100.0% 100.0% 60 C, add sugar and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add tributyrin, homogenise at 350/100 bars, spray dry at 180/80 C Ti/1b.
Example 18: Formulations and Manufacture of Powders with 25% tuna oil in heated blends of NaCas-sugar-HylonMF or NaCas-HylonMF or NaCas-StarPlus MF as encapsulants Ingredient powder emulsion Processing steps (using heat processed and composition com osition microfluidised Hylon VII starch) Water 69.2% Prepare 20%TS starch dispersion at 70 C, Alanate 180 25.0% 7.7% process in 73 x 82 mm cans at 121 C-60 Glucose 25.0% 7.7% minutes, cool down, add remaining water to Hylon VII 25.0% 7.7% make-up to 10% TS, microfluidise at 800 bar-3 Tuna oil 25.0% 7.7% passes. Prepare 15%TS NaCas solution at Total 100.0% 100.0% 60 C, add sugar and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add tuna oil, homogenise at 350/100 bars, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Hylon VII starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Star Plus A) Water 84.6% Prepare 20%TS Star Plus A dispersion at 70 C, Star Plus A 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Star Plus P) Water 84.6% Prepare 20%TS Star Plus P dispersion at 70 C, Star Plus P 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 19: Formulations and Manufacture of Powders with 25% tuna oil (+
Radiolabelled tracer) in heated blends of protein-sugar-RS starch as encapsulants for in-vivo testing.
Ingredient Ingredient emulsion Processing steps (using heat processed and Wt. (g) composition microfluidised Hylon VII starch) Water 82.47 82.04% Prepare 20%TS starch dispersion at 70 C, process Alanate 180 4.33 4.31% in 73 x 82 mm cans at 121 C-60 minutes, cool Glucose 4.33 4.31% down, add remaining water to make-up to 10% IS, Hylon VII 4.33 4.31% microfluidise at 800 bar-3 passes. Prepare 15%TS
Tuna oil 4.56 4.54% NaCas solution at 60 C, add sugar and mix with Radiolabelled 0.50 ml 0.50% processed starch above. (Preferably heat protein-tracer [14C] 18:3 (25 MCi) glucose-starch mixture in cans at 98 C-30 minutes, Total solids 18.05 18.0% cool down to 60 C). Add radiolabelled tuna oil, Total 100.52 100.0% homogenise at 350/100 bars, spray dry at 180/80 C Ti/To.
Characteristics of microcapsules in-vitro The properties of the example I formulations are shown in figure 1 of the drawings. Solvent-extractable fat in all powders (25% fat in powder) were less than 3% (of total fat) indicating that the encapsulating efficiency was good.
Released oil in SGF was less than 2% of total fat for all formulations. Released oil in SGF+SIF
were less than 4% of total fat for casein based microcapsules and up to 22% of total fat for WPI based microcapsules. In these examples NaCas based formulations offer better protection than WPI based formulations. Also heat treatment applied to WPI-sugar encapsulant can increase the release in SGF+SIF.
Depending on the type of protein and whether heat treatment is applied to the encapsulant the core may be released targeted to a specific site in the GI
tract.
The properties of the example 2 formulations are shown in figure 2 of the drawings. Solvent-extractable fat in all powders (50% fat in powder) were less than 3% (of total fat) indicating that the good encapsulating efficiency was maintained when that ratio of the fat to encapsulating material was increased from 1:3 in 25%
fat powders to 1:1 in 50% fat powders. Released oil in SGF was less than 2% of total fat for all formulations. Released oil in SGF+SIF were less than 4% of total fat for casein based microcapsules and up to 30% of total fat for WPI based microcapsules. The trend in the release properties of the microcapsules in Figure 2 with 50% fat powders mirror those observed in Figure 1 for 25% fat powders. In these examples NaCas based formulations offer better protection than WPI based formulations. Also heat treatment applied to WPI-sugar encapsulant can increase the release in SGF+SIF. Depending on the type of protein and whether heat treatment is applied to the encapsulant the core may be released targeted to a specific site in the GI tract.
The properties of the example 3 formulations are shown in figure 3 of the drawings. Formulations (25% fat powders) made with heated protein-starch as encapsulants had low solvent extractable fat (<1 % of total fat). Released oil in SGF was less than 2% of total fat for all formulations. Released oil in SGF+SIF
were less than 4% of total fat for casein based microcapsules and up to 12.5%
of total fat for WPI based microcapsules. In these examples NaCas based formulations offers better protection than the WPI based formulation.
Depending on the type of protein used the core may be released targeted to a specific site in the GI tract.
The properties of the example 4 formulations are shown in figure 4 of the drawings. Formulations (50% fat powders) made with heated protein-starch as encapsulants had higher solvent extractable fat (1 to 20 % of total fat) than corresponding formulation for 25% fat powders. Released oil in SGF was less than 2% of total fat for all formulations. Released oil in SGF+SIF were less than 5% of total fat for casein based microcapsules and up to 15% of total fat for WPI
based microcapsules. In these examples NaCas based formulations offer better protection than the WPI based formulation. Depending on the type of protein used the core may be released targeted to a specific site in the GI tract. Solvent-extractable fat in powder was not related to solvent extractable fat in SGF
and SIF
fluids.
The properties of the example 5 formulations are shown in figure 5 of the drawings. For 25% fat powders the use of gums in combination with protein -glucose/dried glucose syrup or protein -oligosaccharide as encapsulant resulted in powders with low extractable fat in powder (<3% of total fat) and in SGF (<2%
of total fat). Released oil in SGF+SIF were less than 7% of total fat for casein based microcapsules and up to 22.8% of total fat for WPI based microcapsules.
Caseinate-based formulations with gums released more fat (figure 5) than similar formulations without gum (Figure 1) after sequential exposure to SGF and SIF.
In these examples NaCas based formulations offer better protection than WPI based formulations. Depending on the type of protein used the core may be released targeted to a specific site in the GI tract.
The properties of the example 6 formulations are shown in figure 6 of the drawings. The trends observed for 50% fat powders containing gums in combination with protein-glucose/dried glucose syrup or oligosaccharide (Figure 6) are similar to those observed for compositions with 25% fat powders (Figure 5).
All formulations had low extractable fat in powder (<4% of total fat) and SGF
(<2%
of total fat). Released oil in SGF+SIF were less than 5% of total fat for casein based microcapsules and up to 23% of total fat for WPI based microcapsules.
The amount of oil released in 50% fat powders (Figure 6) is significantly more than that in 25% fat powders (figure 5) after sequential exposure to SGF and SIF for WPI
based formulations. In these examples NaCas based formulations offers better protection than WPI based formulations. Depending on the type of protein used the core may be released targeted to a specific site in the GI tract.
The properties of the example 7 formulations are shown in figure 7 of the drawings. Hydrolysed milk proteins can be used in place of whole proteins for encapsulation of oil. For 25% fat powders use of hydrolysed protein in combination with oligosaccharide and polysaccharide as encapsulant resulted in powders with low extractable fat in powder (<3% of total fat). Released oil in SGF was less than 9% of total fat for all formulations. Released oil in SGF+SIF was less than 12% in all formulations. While combinations of hydrolysed casein with oligosaccharide and polysaccharides were less effective for protecting oils from release in SGF+SIF compared to corresponding formulations with the parent protein (Na caseinate), the reverse trend was found with the use of hydrolysed whey protein with oligosaccharide and carrageenan (Compare Figures 5 and 7).
The properties of the example 8 formulations are shown in figure 8 of the drawings. For 50% fat powders use of hydrolysed protein in combination with oligosaccharide and polysaccharide as encapsulant resulted in powders with low extractable fat in powder (<3% of total fat). While solvent-extractable fat in powders (50% fat) was low, the hydrolysed casein-based formulation containing carrageenan released a significant amount of the oil in SGF (77% of total fat) and in SGF+SIF (51% of total fat). This formulation will be a suitable delivery system if the site for target delivery is the stomach or small intestine. Those containing hydrolysed casein or hydrolysed whey protein with high methoxy pectin were comparatively better at protecting their load than those with carrageenan with release in SGF+SIF less than 3% of total fat. In these examples HWP based formulation offers better protection than HCP based formulation. Depending on the type of protein-polysaccharide combination used the core may be released targeted to a specific site in the GI tract.
The properties of the example 9 formulations are shown in figure 9 of the drawings. The results show that 25% fat powders made with unheated and heated combinations of caseinate and raw or pre-processed potato starch had solvent-extractable fat of between 3-8% of total fat, which was generally higher than those made with combinations of proteins with sugar/dried glucose syrup or oligosaccharides. All formulations with potato starch have very low oil release in-vitro. Exposure to SGF resulted in release of <0.6% of total fat and sequential exposure to SGF and SIF resulted in between 4-8% of total fat being released.
The properties of the example 10 formulations are shown in figure 10 of the drawings. The results show that 25% fat powders made with unheated and heated combinations of caseinate and unprocessed or pre-processed Hylon VII had solvent-extractable fat of between 13-26% of total fat, which was generally higher than those made with combinations of proteins with sugar/dried glucose syrup or oligosaccharides or potato starch indicating that encapsulation efficiencies of formulations with Hylon VII were significantly lower. Use of Hylon VII that had been subjected to microfluidisation or extrusion prior to combination with protein improved encapsulation efficiency. All formulations with Hylon VII have very low oil release in-vitro. Exposure to SGF which results in hydration of the capsule resulted in minimal release of <0.8% of total fat and sequential exposure to SGF and SIF
resulted in between 3-7% of total fat being released.
5 The properties of the example 11 formulations are shown in Figure 11 of the drawings. The results show that 25% fat powders made with unheated and heated combinations of caseinate and unprocessed or pre-processed Hi-Maize had solvent-extractable fat of between 13-26% of total fat. Use of Hi-Maize that had been subjected to microfluidisation or extrusion prior to combination with protein 10 improved encapsulation efficiency. All formulations with Hi-Maize have very low oil release in-vitro. Exposure to SGF which results in hydration of the capsule resulted in minimal release of <1% of total fat and sequential exposure to SGF and SIF
resulted in between 4-6% of total fat being released.
15 The properties of the example 12 formulations are shown in figure 12 of the drawings. The results show that 25% fat powders made with unheated and heated combinations of caseinate and unprocessed or pre-processed Novelose 260 had solvent-extractable fat of between 14-25% of total fat. Use of Novelose 260 that had been subjected to microfluidisation prior to combination with protein improved 20 encapsulation efficiency. All formulations with Novelose 260 have very low oil release in-vitro. Exposure to SGF which results in hydration of the capsule resulted in minimal release of <1% of total fat and sequential exposure to SGF and SIF
resulted in between 2-6% of total fat being released. The characteristics of formulations with Novelose 260 were similar to those observed for formulations 25 with Hylon VII (Figure 10) or Hi-Maize (Figure 11), which like Novelose 260 (Figure 12) are RS2 type starches.
The properties of the example 13 formulations are shown in figure 13 of the drawings. The results show that 25% fat powders made with unheated and heated 30 combinations of caseinate and unprocessed or pre-processed Novelose 330 (an RS3 type starch) had solvent-extractable fat of between 13-33% of total fat.
Use of Novelose 330 that had been subjected to extrusion prior to combination with protein improved encapsulation efficiency. All formulations with Novelose 330 have very low oil release in-vitro. Exposure to SGF which results in hydration of the capsule resulted in minimal release of <1 % of total fat and sequential exposure to SGF and SIF resulted in between 3.1 - 8.0 % of total fat being released.
The properties of the example 14 formulations are shown in figure 14 of the drawings. The results demonstrate that pre-processing of starches using emerging food processing technologies (i.e. microfluidisation, high pressure processing or ultrasonication) and extrusion could improve the properties of starches used in combination with casein as delivery systems to the GI tract. Released oil in SGF
was less than 1.2% of total fat for pre-processed starches. Released oil in SGF+SIF was less than 10% in pre-processed starches. All pre-processed starches have lower oil released in-vitro compared to the formulation containing unprocessed starch.
The properties of the example 15 formulations are shown in figure 15 of the drawings. The results demonstrate that use of native non-RS starch and their pre-processed counterparts in combination with protein produced powders with solvent extractable fat of between 5.5-13.6% of total fat. Released oil in SGF was less than 2% of total fat. Released oil in SGF+SIF was between 12-14% (Figure 15), which was slightly higher than that observed when resistant starches were used in combination with protein for microencapsulation (See Figures 9-14).
The properties of the example 16 formulations containing lutein-in-oil are shown in figure 16 of the drawings. The results demonstrate that lutein was protected in the powder microcapsule (0.4-2.5% unencapsulated lutein). Released lutein in SGF
was also very low (2.5-4% of total lutein). Released lutein in SGF+SIF was between 34-51% (Figure 16).
The properties of the example 17 formulations containing tributyrin are shown in figure 17 of the drawings. All the tributyrin was released after sequential exposure to SGF and SIF in NaCas-sugar formulation, and up to 83% in NaCas-sugar-RS
starch formulation. These results suggest that formulation with RS starch has improved the protection of tributyrin in the GI tract.
The properties of the example 18 formulations containing 25% tuna oil in heated blends of NaCas-sugar-HylonMF or NaCas-HylonMF or NaCas-StarPlus MF as encapsulants are shown in figure 18 of the drawings. The results demonstrate that addition of Glucose into an NaCas-Hylon formulation can improve the encapsulation efficiency of the powder microcapsule without affecting the release in SGF and SGF+SIF. Use of acetylated starch (StarPlus A) or proprionylated starch (Starplus P) in place of Hylon in formulations containing resistant starch in combination with NaCas increased the release in SGF+SIF from 5% for Hylon to 12% and 25% for Star Plus A and StarPlus P respectively (Figure 18), but there was no difference in the amount of release in SGF.
Release characteristics of tuna oil microcapsules in-vivo The result of the in-vivo experiment (example 19 formulation) is shown in figures 19a and 19b of the drawings. Lumen contents were expressed as a percentage of dose of radioactivity given to indicate relative abundance between the treatment groups. The figures show the percentage of administered dose of radioactivity recovered after dosing with C14 trilinolenein as free oil after 4, 9, and 14 hours.
This includes lumen contents, tissue and faeces. Data is expressed as percentage of total lumen radioactivity to show relative distribution across the system.
All rats n=5 in each case except for fig 19b at 14 hours where n=4.
The results indicated that the treatment with microencapsulated oil at 9 hours resulted in greater caecum and colon (18% and 35%) radioactivity (Figure 19a) than treatment with free oil, where only about 5% in caecum at 4 hours and about 10% in colon at 4 hours, with minimal amounts of radioactivity at 9 hours (Figure 19b). Radioactivity levels in the lumen for the treatment with free oil were low at all time points, which indicates that even by 4 hours there may be significant uptake and metabolism to CO2. Overall the in-vivo study indicates that the process of microencapsulation was reasonably successful in protecting the fish oil against early uptake and metabolism in the stomach and upper GI tract. For the treatment with microencapsulated oils the recovery was high at 4 and 9 hours, and at these time points the radioactivity was either in the stomach at 4 hours or caecum and colon at 9 hours. High amounts in the caecum and colon indicates that the microencapsulated oil passed the small intestine without significant absorption.
For the free oil, smaller amounts reached the caecum and colon, primarily because the recovery of the given dose was low at all time points indicating greater metabolism. Even at 4 hour time point the oil had already transited the small intestine. There was little radiolabel retained in the tissues at 14 hour in either group, which indicates that conversion to endogenous lipids was not significant.
From the above those skilled in the art will see that the present invention provides a simple to use yet effective delivery vehicle to the colon as well as preserving sensitive core ingredients during storage and processing. Those skilled in the art will also realise that this invention can be implemented in a number of different embodiments by varying the encapsulant proteins and carbohydrates without departing from the teachings of this invention.
The agents that may be encapsulated include lipids (oils including oxygen sensitive oils, fatty acids, triglycerides) and oil soluble and oil dispersible ingredients (including pharmaceuticals, probiotics, and bioactives). Water dispersible components including those that partition between oil and water phases may also be encapsulated. When water dispersible therapeutic and nutritional agents are used they may not be encapsulated with the oil phase but may be dispersed in the encapsulant film. The emulsions may be used as food ingredients or therapeutic agents but preferably the emulsions are dried to form powders.
Prior art encapsulation systems did not consider the use of combinations of proteins with other biopolymers for formation of capsules for target delivery of sensitive cores to the colon.
The delivery systems of this invention enable pharmaceutical and food manufacturers to offer a range of nutritionally and physiologically functional food ingredients and bioactive compounds in convenient formats and using all natural ingredients which will also enable the delivery of these products to the colon.
Some of the encapsulants used for colon delivery in this invention have the added benefits of being effective matrices for encapsulating oxygen sensitive ingredients.
The film-forming and anti-oxidant properties of some of the encapsulants used work synergistically to preserve sensitive ingredients such as polyunsaturated fatty acids from being oxidised during storage and also protects them during exposure to high temperature, pressure and moisture encountered during the processing of foods. In addition, this invention uses readily available proteins and carbohydrates.
There are no solvents used in the preparation of the encapsulated formulations as the process is an all-aqueous based system. The processes can be easily incorporated or adapted to suit most food and pharmaceutical manufacturing plants with drying operations.
The protein used may include any film forming water soluble protein or hydrolysed protein and includes milk proteins such as casein and its derivatives or whey proteins. The carbohydrate component may be those containing reducing sugar groups, oligosaccharides and starches (raw, modified, resistant, acetylated, proprionated and butylated starches).
The proteins and carbohydrates may be reacted in aqueous solutions to obtain 5 conjugates. The reaction, which occurs, can be between free amine groups of amino acids in the protein and reducing sugar groups in the carbohydrate. This type of reaction is generally termed a Maillard reaction typically occurring in the non-enzymatic browning of foods. This reaction occurs during heat processing of foods and has previously been shown to be beneficial for engineering desirable encapsulating properties for protection of oxygen sensitive components. For example, microencapsulated formulations containing oxygen sensitive oils are protected against oxidation as the Maillard reaction products [MRP] in the encapsulating matrix are good film-formers and also exhibit anti-oxidation activity as disclosed in WO 01/74175.
The starches used in the formulations may also be pre-processed using conventional and emerging processing technologies to modify the starch properties to provide improved processing characteristics during the preparation of the delivery systems. The pretreatments are chosen to break down the long starch molecules so that they form more stable emulsions and also to provide a larger number of terminal sugar reducing groups for Maillard reaction with the protein component of the encapsulant.
Colon delivery systems may be used for range of bioactives (e.g. oils), pharmaceuticals and therapeutics, which are unstable in the upper gastrointestinal tract. The protection afforded to the encapsulated components by the encapsulating material enable target release in the colon where the release is achieved after the encapsulant is degraded (e.g. by the action of microbial enzymes in the colon). Delivery of bioactives, pharmaceuticals and therapeutic components to the colon is desirable for treatment and prevention of diseases of the colon such as colorectal cancer, ulcerative colitis and inflammatory bowel disorder.
In some cases the encapsulants used in the formulations such as selected polysaccharides, can also serve as gut wall adherents or as prebiotics that facilitate growth of beneficial bacteria, and can offer added advantages. For b example delivery systems containing resistant starch have potential benefits on colonic health.
Detailed Description of the invention A number of formulations will be described, some according to the invention and some for comparative purposes to show that some formulations are suitable to delivery to the colon whilst others could be more suitable for release in the small intestine. These formulations demonstrate that the core is protected from digestion in the stomach and the environment in the small intestine.
Figures 1 to 19 of the drawings graphically illustrate the solvent extractable fat content and other properties of the formulations of the Invention as illustrated in examples I to 19 below.
The process of microencapsulating the active component involves the following manufacturing steps:
(a) Selection of the biologically active core (e.g. oil, oil soluble or oil dispersible material, bioactives, therapeutics, pharmaceuticals) (b) Dispersion of the protein and carbohydrates (or starch that has been pre-processed by conventional means such as heating or extrusion or by the use of emerging processing technologies such as high pressure processing, microfluidisation or ultrasonics) in the aqueous phase and treatment of the mixture. If desired, the protein-carbohydrate blends may be further heat processed to induce the formation of conjugates (e.g. Maillard reaction products) (c) Mixing the core with the encapsulant (i.e. protein-carbohydrate mixture) and homogenizing the mixture to obtain an emulsion, in which the core is surrounded by the encapsulant.
(d) Optionally, spray drying the emulsion to obtain a powdered formulation in which the core is surrounded by the encapsulating matrix 6a In one particular embodiment, there is provided a method of preparing microcapsules for use in storing storage unstable, therapeutic and nutritional agents for targeted delivery to predetermined locations in the gastrointestinal tract which includes the steps of:
a) selecting a nutritional or therapeutic oil, oil soluble or oil dispersible nutritional or therapeutic agent to form an oil phase b) dispersing a water soluble film forming protein and a treated resistant starch in the aqueous phase c) mixing component (a) with component (b) and homogenizing the mixture to obtain an oil-in-water emulsion d) optionally drying the emulsion to obtain a powdered formulation in which the nutritional or therapeutic oil or agent is surrounded by the component (b) thereby encapsulating the storage unstable, therapeutic or nutritional agent.
In another embodiment there is provided an encapsulation material for use with storage unstable, therapeutic and nutritional agents which releases the therapeutic and nutritional agents in predetermined locations in the gastrointestinal tract and in which the encapsulation material is formed by combining a food grade treated resistant starch with a water soluble food grade protein.
The invention further provides an orally administrable nutritional or therapeutic product for delivery of a nutritional or therapeutic agent to the gastrointestinal tract in which the agent comprises an oil or an oil soluble or dispersible component which is encapsulated in a material as described herein.
Emulsion formulations Tuna fish oil was used as an oil of choice in most of these examples since it contains a high amount of long chain polyunsaturated fatty acids and this needs to be protected from oxidation prior to consumption. In addition there is interest in delivering these to the colon because of their potential for prevention of colorectal cancer and promotion of bowel health (Karmeli, R A. (1996) Historical Perspective and Potential Use of n-3 Fatty Acids in Therapy of Cancer Cachia. Nutrition, Vol 12 (1) S2-S4; Dommels Y E M, Alink, G M, van Bladeren, P J, van Ommen, B (2002) Dietary n-6 and n-3 polyunsaturated fatty acids and colorectal carcinogenesis:
results from cultured colon cells, animal models and human studies, Environmental Toxicology and Pharmacology, Vol 12 (4), 233-244.). Tributyrin and lutein were also included as examples. The encapsulation of probiotics (i.e. an example of a water dispersible component) using this technology has been previously disclosed in WO 01174175.
A range of formulations was prepared using protein and/or carbohydrate (raw or pre-processed) and oil mixtures at different ratios. The formulations were made-up to contain 25 and 50% fat In the final powder:
The protein used in these examples were sodium caseinate, whey protein isolate and hydrolysed milk proteins. The carbohydrates used, alone or in combination, were glucose, oligosaccharides, dried glucose syrup, modified starches, resistant starches and native starches. Polysaccharides, including high-methoxy pectin, alginate, carrageenan, guar gum, were added to protein-carbohydrate mixtures in some formulations.
Manufacture of microcapsules Materials The core materials used in the examples include: tuna oil, tributyrin and 15%
(w/w) lutein (mostly as dipalmitate and dimyristate lutein esters) in soy bean oil.
Proteins used as encapsulant in the examples include: sodium caseinate (NaCas), whey protein isolate (WPI), hydrolysed casein protein (HCP) and hydrolysed whey protein (HWP).
Carbohydrates used in the examples include: dextrose monohydrate (Glu), waxy maize, maize starch, dried glucose syrup (DGS), wheat starch, oligofructose (oligo), tapioca dextrin (K4484), modified starch (CapsulT"'), modified starch (Hi-CapTM 100), Hi-MaizeTM, HylonTM VII, NoveloseTM 260 and Novelose 330, potato starch, sodium alginate, kappa carrageenan, high methoxy pectin (HMP) and guar gum.
Preparation of protein-carbohydrate encapsulants In some cases, unreacted blends of protein and carbohydrates (referred to as NonMRP formulations since these were not heated to induce the formation of Maillard reaction products) were used as the encapsulating matrix. For the preparation of reacted protein-carbohydrate encapsulants (referred to as MRP
formulations as these were heated to induce the formation of Maillard reaction products), protein was dissolved in 60 C water, using a high shear mixer, and then the sugars, starch or the selected carbohydrate were added. Where a polysaccharide was also added, the polysaccharide was first allowed to hydrate in water at 90 C temperature before addition into the protein-sugar mixture. The pH
of the protein-sugar/starch /gum mixtures was adjusted to 7.5. The mixture were then filled into 3 litre cans, sealed and heated in the retort to 98 C and held for 30 minutes, then cooled down to room temperature. Microcapsule formulations are given in the examples below together with the methods used for the manufacture of microcapsules.
Preparation of protein-starch encapsulants Protein was dissolved in 60 C water to make 15% total solids (TS) solution, using a high shear mixer. Starch (raw or heated, heated and microfluidised, extruded, high pressure processed and ultrasonicated) was prepared and processed separately to make a 10% TS solutions or dispersions in 70 C water (See Preparation of Starches for Microencapsulation detailed below). The 15%TS
protein solution were mixed together with the 10%TS starch to get a 12%TS
mixture with a 1:1 protein:starch ratio. Where MRP was required, the mixture were then filled into 3 litre cans, sealed and heated in the retort to 98 C and held for 30 minutes, then cooled down to 60 C.
Preparation of Starches for Microencapsulation Raw or Unprocessed 10% TS starch dispersion (no pre-treatment applied) was mixed with 15% TS of protein solution at 60 C.
Heat processing 20% TS of each starch dispersion (except for potato starch where a 10% TS
dispersion was used due to high viscosity at 20% TS) were heated at 121 C for minutes in a 73x82 mm cans. Once heat processed, 70 C deionised water was added to dilute the sample to 10% TS in a high shear mixer. This heat processed starch was mixed with 15% TS of protein solution at 60 C. This mixture was then used for microencapsulation of bioactives.
Heat processing and Micro fluidisation treatment 20% TS of each starch dispersion (except for potato starch where a 10% TS
dispersion was used due to high viscosity at 20% TS) were heated at 121 C for minutes in a 73x82 mm cans. Once heat processed, 70 C deionised water was added to dilute the sample to 10% TS in a high shear mixer, and processed at 60 C through a pilot scale M-210B EH microfluidiser (MFIC, Newton MA, USA).
The plant was operated at 800 bars and 3 passes using a combination of 425 pm Q50Z auxiliary processing module and 200 pm E230Z interaction chamber (for dispersion and cell disruption). The microfluidised (MF) starch was mixed with 15% TS of protein solution at 60 C for microencapsulation.
Heat processing and Ultra-high pressure treatment 20% TS of a starch dispersion was heated at 121 C for 60 minutes ina 73x82 mm cans. Once heat processed, 70 C deionised water was added to dilute the sample to 10% TS in a high shear mixer, and processed by ultra-high pressure treatment at 6,000 bars for 15 minutes using HPP-QFP 35L unit. The ultra-high pressure treated (HPP) starch was mixed with 15% TS of protein solution at 60 C for microencapsulation.
Heat processing and Ultrasonics treatment 20% TS of a starch dispersion was heated at 121 C for 60 minutes in 73x82 mm cans. Once heat processed, 70 C deionised water was added to dilute the sample to 10% in a high shear mixer, and processed with ultrasound treatment at 50 ml/min @ 380 watts using 20KHz unit. The ultrasound treated (US) starch was mixed with 15% TS of protein solution at 60 C for microencapsulation.
Extrusion Resistant starches were processed using a twin-screw extruder (model MPF 40, APV Baker, Peterborough PE3-6TA, England) 40mm screw diameter and length,to diameter ratio of 25:1, and a low shear screw configuration. A 4 mm die was used throughout the trial. Raw materials were fed into feed port 1 at 15 kg h-' for resistant starch processing using a gravimetric feeder (Ktron Soder AG CH-5702, Niederlenz) and water was injected into port 2 with a volumetric pump (Brook Crompton, Huddersfield, England). Barrel moisture was injected at 20-40 % and the die melt temperature was varied from 140 to 178 C with increasing screw speed from 150-250rpm. The extruded resistant starches were milled to 0.2mm particle size powder. 10% TS extruded starch dispersion was mixed with 15% TS
5 of protein solution at 60 C for microencapsulation.
Preparation of oil in water emulsions The protein-carbohydrate mixtures and the tuna oil were pre-heated to 60 C
separately. The bioactive core was added into the protein-carbohydrate mixture using a Silverson high shear mixer. The mixture were then homogenised at 350 10 and 100 bar pressures in two stages using a Rannie homogeniser.
Spray drying of emulsions The homogenised emulsions were spray dried at 50-60 C feed temperature, 180 C inlet temperature and 80 C outlet temperature using a Niro production minor spray dryer. The powder was collected from the main chamber and packed.
Estimation of solvent extractable fat in tuna oil powders The estimation of solvent-extractable was based on the method by Pisecky (Handbook of Milk Powder Manufacture, 1997) except that petroleum ether was used in place of carbon tetrachloride. Fifty ml of petroleum ether (b.p. 40-60 C) was added to 10g powder. The mixture was agitated in a stoppered flask for 15 minutes. The mixture was filtered and the solvent evaporated at 60 C using a rotary evaporator. The remaining fat residue was then dried in an oven at 105 C
for 1 h.
In-vitro testing of microcapsules The stability of the microcapsules in the stomach and the small-intestine was u estimated by assessment of oil-release properties of microcapsules (a) incubated in simulated gastric fluid (SGF) (pH 1.2) for 2h at 37 C and 100 rpm in a shaker water-bath incubator and (b) incubated in SGF (2 h at 37 C and 100 rpm in a shaker water-bath incubator) followed by exposure to simulated intestinal fluid (SIF) (pH 6.8) (3 h at 37 C and 100 rpm). SGF and SIF were prepared according to the methods given in the US Pharmacopeia (US Pharmacopeia 2000 &
National Formulatory (USP 24 NF 19), Rockville, MD) For estimation of released oil from microcapsules in-vitro:
The solvent extractable fat from the incubated samples were measured. The sample was transferred into a 250 ml stoppered separating funnel and extracted with petroleum ether (75 ml plus 2x25m1). The sample was filtered through a phase separation filter paper to obtain. the solvent phase after each extraction.
The solvent was removed to recover the oil released.
For estimation of released lutein in-vitro:
The microcapsule containing the lutein (1.0 g) was incubated sequentially with SGF (pH 1.2) and SIF (pH6.8) as outlined above. For estimation of released lutein, the solvent extractable lutein from the incubated samples was measured.
The extraction was performed in a centrifuge tube. The sample was extracted with petroleum ether (15 ml plus 2xlOml). The sample was centrifuged (2000 rpm for 10 min) after each extraction and the top solvent layer removed. The combined solvent extracts were filtered through a phase separation filter paper prior to dilution with petroleum ether. The absorbance of the diluted extract was measured at 444 nm and the concentration of extracted lutein was determined.
For estimation of released Tributyrin in-vitro:
The microcapsule containing the tributyrin (1.0 g) was incubated sequentially with SGF (pH 1.2) and SIF (pH 6.8) as outlined above. For estimation of released tributyrin samples that were exposed to SGF only were used directly and that exposed sequentially to SGF and SIF was adjusted to pH 2. To this mixture was added 2.5 g NaCl and 15 ml dichloromethane and the mixture was centrifuged at 2500 rpm for 10 min at 5 C. The aqueous layer was removed and kept while the dichloromethane layer was decanted into a conical flask without disturbing the gelatinous precipitate floating on top of the dichloromethane layer. The aqueous layer with the gelatinous precipitate was extracted with another 15 ml dichloromethane. The dichloromethane extracts were dried over anhydrous Na2SO4, before filtering (0.45 pm PTFE syringe filter). The dichloromethane was removed under Nitrogen in a warm water bath. The extracted material was dissolved in 10 ml hexane/iso-propyl alcohol (99:1, v/v) and the solution stored in freezer. The amount of tributyrin and butyric acid in the extract was analysed by normal-phase HPLC. [Column: PVA-Sil guard and analytical (250mm x 4.6 mm I.D.) columns; UV detector (210 nm)].
In-vivo testing of microcapsules Male Sprague-Dawley rats, approximately 10 weeks of age were used for the in-vivo study. Rats were denied solid food for 24 hours prior to dosing, but were allowed free access to drinking water containing 2.5% glucose, 0.5% NaCl and 0.005% KCI (all w/v).
Preparation of radiolabelled tuna oil: 0.5 ml or 25 pCi radiolabelled tracer [1-14C]
18:3 ([14C] trilinolenin, 50-60 mCi/mmol; 50 pCi/mL) was added to 4.56 g tuna oil.
Two lots of tuna oil samples with radiolabelled trilinolenin were prepared, one for encapsulated oil treatment (see example 19 for formulation and manufacture) and one for free (unencapsulated) oil treatment.
Rat treatment: On the day of treatment rats were fed intra-gastrically using a stainless steel gavage needle either with 0.3 ml fish oil mixed with radiolabelled tracer [14C] 18:3 (0.27 g tuna oil + 0.03 ml tracer [14C] 18:3) for control treatment or 2 ml emulsion (0.09 g tuna oil + 0.01 ml tracer [14C] 18:3) for the microencapsulated treatment.
Tissue sampling: At time points of 4, 9 and 14 hours following treatment, rats were anesthetised and a blood sample taken by cardiac puncture. The stomach, small intestine, caecum and colon were removed. The small intestine was divided into two sections, each GI tract segment was flushed with 0.9% NaCl and the washings collected and frozen. The GI tract segments were then frozen for subsequent analysis. Faeces were also collected for analysis at time points. The tissues and faeces were weighed and samples taken for analysis and weighed.
Tissue sample analysis: Radioactivity of GI tract washings containing all unabsorbed oil (both released and encapsulated oil) was counted to estimate the total amount of radioactivity. Tissue samples were dissolved overnight in BTS-450R tissue solubiliser. Faecal matters were dissolved in BTS-4508, with some prior treatment. The liquid scintillation cocktail Ready Organic R was added to each sample and the sample subjected to liquid scintillation counting in a Packard 1500 Tri-Carb Scintillation Counter.
Example 1: Formulations and Manufacture of Powders with 25% oil loading with unheated or heated blends of protein-glucose/dried glucose syrup or protein-oligosaccharide as encapsulants Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare NaCas solution (Alanate) at 60 C, add Alanate 180 25.0% 7.7% sugars [glucose and DGS (Maltostar)], Glucose.H20 25.0% 7.7% (preferably, adjust pH of solution to 7.5, heat to Maltostar 30 25.0% 7.7% 98 C and hold for 30 minutes, cool down to Tuna oil 25.0% 7.7% 60 C), add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Inlet Total 100.0% 100.0% temperature Ti /Outlet temperature (To).
Ingredient powder Emulsion Processing steps composition compositio Water 69.2% Prepare NaCas solution at 60 C, add Alanate 180 25.0% 7.7% oligosaccharide, (preferably, adjust pH of Raftilose P95 50.0% 15.4% solution to 7.5, heat to 98 C and hold for 30 Tuna oil 25.0% 7.7% minutes, cool down to 60 C), add oil heated to 60 C, homogenise at 350/100 bar, spray dry at Total 100.0% 100.0% 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare WPI solution (Alacen) at 60 C, add Alacen 895 25.0% 7.7% sugars, (preferably, adjust pH of solution to 7.5, Glucose.H20 25.0% 7.7% heat to 98 C and hold for 30 minutes, cool down Maltostar 30 25.0% 7.7% to 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 7.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare WPI solution at 60 C, add Alacen 895 25.0% 7.7% oligosaccharidesugars, (preferably, adjust pH of Raftilose P95 50.0% 15.4% solution to 7.5, heat to 98 C and hold for 30 Tuna oil 25.0% 7.7% minutes, cool down to 60 C), add oil heated to Total 100.0% 100.0% 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 2: Formulations and Manufacture of Powders with 50% oil loading with unheated or heated blends of protein- glucose/dried glucose syrup or protein-oligosaccharide as encapsulants Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare NaCas solution at 60 C, add sugars, Alanate 180 16.7% 6.7% (preferably, adjust pH of solution to 7.5, heat to Glucose.H20 16.7% 6.7% 98 C and hold for 30 minutes, cool down to Maltostar 30 16.7% 6.7% 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 20.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare NaCas solution at 60 C, add Alanate 180 16.7% 6.7% oligosaccharide (Raftilose), (preferably, adjust pH
Raftilose P95 33.3% 13.3% of solution to 7.5, heat to 98 C and hold for 30 Tuna oil 50.0% 20.0% minutes, cool down to 60 C), add oil heated to Total 100.0% 100.0% 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare WPI solution at 60 C, add sugars, Alacen 895 16.7% 6.7% (preferably, adjust pH of solution to 7.5, heat to Glucose.H20 16.7% 6.7% 98 C and hold for 30 minutes, cool down to Maltostar 30 16.7% 6.7% 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 20.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare WPI solution at 60 C, add Alacen 895 16.7.0% 6.7% oligosaccharidesugars, (preferably, adjust pH of Raftilose P95 33.3% 13.3% solution to 7.5, heat to 98 C and hold for 30 Tuna oil 50.0% 20.0% minutes, cool down to 60 C), add oil heated to 60 C, homogenise at 350/100 bar, spray dry at Total 100.0% 100.0% 180/80 C Ti/To.
Example 3: Formulations and Manufacture of Powders with 25% oil loading with heated blends of protein- starch as encapsulants Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare NaCas solution at 60 C, add starch Alanate 180 25.0% 7.7% (Capsul), (preferably, adjust pH of solution to 7.5, Capsul 50.0% 15.4% heat to 98 C and hold for 30 minutes, cool down Tuna oil 25.0% 7.7% to 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare NaCas solution at 60 C, add starch (Hi-Alanate 180 25.0% 7.7% Cap), (preferably, adjust pH of solution to 7.5, Hi-Cap 100 50.0% 15.4% heat to 98 C and hold for 30 minutes, cool down Tuna oil 25.0% 7.7% to 60 C), add oil heated to 60 C, homogenise at Total ~---100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare NaCas solution at 60 C, add dextrin, Alanate 180 25.0% 7.7% (preferably, adjust pH of solution to 7.5, heat to Tapioca dextrin 50.0% 15.4% 98 C and hold for 30 minutes, cool down to K4484 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 7.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare WPI solution at 60 C, add dextrin, Alacen 895 25.0% 7.7% (preferably, adjust pH of solution to 7.5, heat to Tapioca dextrin 50.0% 15.4% 98 C and hold for 30 minutes, cool down to K4484 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 7.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Example 4: Formulations and Manufacture of Powders with 50% oil loading with 5 heated blends of protein- starch as encapsulants Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare NaCas solution at 60 C, add starch, Alanate 180 16.7% 6.7% (preferably, adjust pH of solution to 7.5, heat to Capsul 33.3% 13.3% 98 C and hold for 30 minutes, cool down to Tuna oil 50.0% 20.0% 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare NaCas solution at 60 C, add starch, Alanate 180 16.7% 6.7% (preferably, adjust pH of solution to 7.5, heat to Hi-Cap 100 33.3% 13.3% 98 C and hold for 30 minutes, cool down to Tuna oil 50.0% 20.0% 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare NaCas solution at 60 C, add dextrin, Alanate 180 16.7% 6.7% (preferably, adjust pH of solution to 7.5, heat to Tapioca dextrin 33.3% 13.3% 98 C and hold for 30 minutes, cool down to K4484 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 20.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 60.0% Prepare WPI solution at 60 C, add dextrin, Alacen 895 16.7% 6.7% (preferably, adjust pH of solution to 7.5, heat to Tapioca dextrin 33.3% 13.3% 98 C and hold for 30 minutes, cool down to K4484 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 20.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Example 5: Formulations and Manufacture of Powders with 25% oil loading with heated blends of protein-glucose/glucose syrup or protein-oligosaccharide in combination with gums as encapsulants Ingredient powder emulsion Processing steps composition com osition Water 69.2% Prepare NaCas solution at 60 C, add sugars and Alanate 180 25.0% 7.7% alginate (Protanal), (preferably, adjust pH of Glucose.H20 25.0% 7.7% solution to 7.5, heat to 98 C and hold for 30 Maltostar 30 22.5% 6.9% minutes, cool down to 60 C), add oil heated to Protanal 2.5% 0.8% 60 C, homogenise at 350/100 bar, spray dry at Tuna oil 25.0% 7.7% 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 77.7% Prepare NaCas solution at 60 C, add Alanate 180 25.0% 5.6% oligosaccharide and guar gum solution, Raftilose P95 48.75% 10.9% (preferably, adjust pH of solution to 7.5, heat to Guar 1.25% 0.3% 98 C and hold for 30 minutes, cool down to WW250F 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 5.6% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 73.2% Prepare NaCas solution at 60 C, add Alanate 180 25.0% 6.7% oligosaccharide and carrageenan solution Raftilose P95 48.75% 13.0% (Gelcarin), (preferably, adjust pH of solution to Gelcarin 1.25% 0.3% 7.5, heat to 98 C and hold for 30 minutes, cool GP 812 down to 60 C), add oil heated to 60 C, Tuna oil 25.0% 6.7% homogenise at 350/100 bar, spray dry at Total 100.0% 100.0% 180/80 C Ti/To.
Ingredient powder emulsion Processing steps com osition composition Water 73.1% Prepare NaCas solution at 60 C, add Alanate 180 25.0% 6.7% oligosaccharide and high methoxy pectin (HMP) Raftilose P95 47.5% 12.7% solution, (preferably, adjust pH of solution to 7.5, HMP RS400 2.5% 0.7% heat to 98 C and hold for 30 minutes, cool down Tuna oil 25.0% 6.7% to 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 73.1% Prepare NaCas solution at 60 C, add glucose-Alacen 895 25.0% 6.7% DGS and high methoxy pectin (HMP) solution, 1:1 GIu:DGS 47.5% 12.7% (preferably, adjust pH of solution to 7.5, heat to HMP RS400 2.5% 0.7% 98 C and hold for 30 minutes, cool down to Tuna oil 25.0% 6.7% 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition compositio Water 77.7% Prepare WPI solution at 60 C, add Alacen 895 25.0% 5.6% oligosaccharide and guar gum solution, Raftilose P95 48.75% 10.9% (preferably, adjust pH of solution to 7.5, heat to Guar 1.25% 0.3% 98 C and hold for 30 minutes, cool down to WW250F 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 5.6% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 73.2% Prepare NaCas solution at 60 C, add Alacen 895 25.0% 6.7% oligosaccharide and 60 C carrageenan solution, Raftilose P95 48.75% 13.0% (preferably, adjust pH of solution to 7.5, heat to Gelcarin 1.25% 0.3% 98 C and hold for 30 minutes, cool down to GP 812 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 6.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition water 73.1% Prepare NaCas solution at 60 C, add Alacen 895 25.0% 6.7% oligosaccharide and 60 C HMP solution, Raftilose P95 47.5% 12.7% (preferably, adjust pH of solution to 7.5, heat to HMP RS400 2.5% 0.7% 98 C and hold for 30 minutes, cool down to Tuna oil 25.0% 6.7% 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Example 6: Formulations and Manufacture of Powders with 50% oil loading with heated blends of protein-glucose/glucose cose/glucose syrup or protein-oligosaccharide in combination with gums as encapsulants Ingredient powder emulsion Processing steps composition composition water 60.0% Prepare NaCas solution at 60 C, add sugars and Alanate 180 16.7% 6.7% alginate, (preferably, adjust pH of solution to 7.5, Glucose 16.7% 67% heat to 98 C and hold for 30 minutes, cool down Maltostar 30 15.0% 6.0% to 60 C), add oil heated to 60 C, homogenise at Protanal 1.7% 0.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Tuna oil 50.0% 20.0%
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 69.9% Prepare HWP solution at 60 C, add NaCas 16.7% 5.0% oligosaccharide and guar gum solution, Raftilose P95 32.5% 9.8% (preferably, adjust pH of solution to 7.5, heat to Guar 0.8% 0.3% 98 C and hold for 30 minutes, cool down to WW250F 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 15.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 64.6% Prepare NaCas solution at 60 C, add Alanate 180 16.7% 5.9% oligosaccharide and carrageenan solution, Raftilose P95 32.5% 11.5% (preferably, adjust pH of solution to 7.5, heat to Gelcarin 0.8% 0.3% 98 C and hold for 30 minutes, cool down to GP 812 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 17.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 64.5% Prepare NaCas solution at 60 C, add Alanate 180 16.7% 5.9% oligosaccharidesugars and HMP solution, Raftilose P95 31.7% 11.2% (preferably, adjust pH of solution to 7.5, heat to HMP RS400 1.7% 0.6% 98 C and hold for 30 minutes, cool down to Tuna oil 50.0% 17.8% 60 C), add oil heated to 60 C, homogenise at Total 100.0% 100.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 69.9% Prepare WPI solution at 60 C, add Alacen 895 16.7% 5.0% oligosaccharide and guar gum solution, Raftilose P95 32.5% 9.8% (preferably, adjust pH of solution to 7.5, heat to Guar 0.8% 0.3% 98 C and hold for 30 minutes, cool down to WW250F 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 15.0% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 53.1% Prepare WPI solution at 60 C, add Alacen 895 16.7% 5.9% oligosaccharide and carrageenan solution, Raftilose P95 32.5% 11.5% (preferably, adjust pH of solution to 7.5, heat to Gelcarin 0.8% 0.3% 98 C and hold for 30 minutes, cool down to GP 812 60 C), add oil heated to 60 C, homogenise at Water for gum 11.5% 350/100 bar, spray dry at 180/80 C Ti/To.
dispersion Tuna oil 50.0% 17.7%
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 53.3% Prepare WPI solution at 60 C, add Alacen 895 16.7% 5.9% oligosaccharide and 60 C HMP solution, Raftilose P95 31.7% 11.2% (preferably, adjust pH of solution to 7.5, heat to HMP RS400 1.7% 0.6% 98 C and hold for 30 minutes, cool down to Water for gum 11.2% 60 C), add oil heated to 60 C, homogenise at dispersion 350/100 bar, spray dry at 180/80 C Ti/To.
Tuna oil 50.0% 17.8%
Total 100.0% 100.0%
Example 7: Formulations and Manufacture of Powders with 25% oil loading with heated blends of protein hydrolysate - oligosaccharide in combination with gums as encapsulants Ingredient powder emulsion Processing steps composition composition Water 73.2% Prepare hydrolysed casein protein (HCP) HCP 102 25.0% 6.7% solution at 60 C, add oligosaccharide, and 60 C
Raftilose P95 48.75% 13.0% carrageenan solution (preferably, adjust pH of Gelcarin 1.25% 0.3% solution to 7.5, heat to 98 C and hold for 30 GP 812 minutes, cool down to 60 C), add oil heated to Tuna oil 25.0% 6.7% 60 C, homogenise at 350/100 bar, spray dry at Total 100.0% 100.0% 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 73.1% Prepare HCP solution at 60 C, add HCP 102 25.0% 6.7% oligosaccharide and HMP solution, (preferably, Raftilose P95 47.5% 12.7% adjust pH of solution to 7.5, heat to 98 C and HMP RS400 2.5% 0.7% hold for 30 minutes, cool down to 60 C), add of 1 Tuna oil 25.0% 6.7% heated to 60 C, homogenise at 350/100 bar, Total 100.0% 100.0% spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 73.2% Prepare hydrolysed whey protein (HWP) solution HWP 205 25.0% 6.7% at 60 C, add oligosaccharide and carrageenan Raftilose P95 48.75% 13.0% solution, (preferably, adjust pH of solution to 7.5, Gelcarin 1.25% 0.3% heat to 98 C and hold for 30 minutes, cool down GP 812 to 60 C), add oil heated to 60 C, homogenise at Tuna oil 25.0% 6.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 73.1% Prepare HWP solution at 60 C, add HWP 205 25.0% 6.7% oligosaccharide and HMP solution, (preferably, Raftilose P95 47.5% 12.7% adjust pH of solution to 7.5, heat to 98 C and HMP RS400 2.5% 0.7% ' hold for 30 minutes, cool down to 60 C), add oil Tuna oil 25.0% 6.7% heated to 60 C, homogenise at 350/100 bar, Total 100.0% 100.0% spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 73.1% Prepare HWP solution at 60 C, add glucose-HWP 205 25.0% 6.7% DGS and HMP solution, (preferably, adjust pH of 1:1 Glu:DGS 47.5% 12.7% solution to 7.5, heat to 98 C and hold for 30 HMP RS400 2.5% 0.7% minutes, cool down to 60 C), add oil heated to Tuna oil 25.0% 6.7% 60 C, homogenise at 350/100 bar, spray dry at Total 100.0% 100.0% 180/80 C Ti/To.
Example 8: Formulations and Manufacture of Powders with 50% oil loading with heated blends of hydrolysate - oligosaccharide in combination with gums as encapsulants Ingredient powder emulsion Processing steps composition composition Water 64.6% Prepare HCP solution at 60 C, add HCP 102 16.7% 5.9% oligosaccharide and carrageenan solution, Raftilose P95 32.5% 11.5% (preferably, adjust pH of solution to 7.5, heat to Gelcarin 0.8% 0.3% 98 C and hold for 30 minutes, cool down to GP 812 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 17.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 64.5% Prepare HCP solution at 60 C, add HCP 102 16.7% 5.9% oligosaccharide and HMP solution, (preferably, Raftilose P95 31.7% 11.2% adjust pH of solution to 7.5, heat to 98 C and HMP RS400 1.7% 0.6% hold for 30 minutes, cool down to 60 C), add oil Tuna oil 50.0% 17.8% heated to 60 C, homogenise at 350/100 bar, Total 100.0% 100.0% spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 64.6% Prepare HWP solution at 60 C, add HWP 205 16.7% 5.9% oligosaccharide and carrageenan solution, Raftilose P95 32.5% 11.5% (preferably, adjust pH of solution to 7.5, heat to Gelcarin 0.8% 0.3% 98 C and hold for 30 minutes, cool down to GP 812 60 C), add oil heated to 60 C, homogenise at Tuna oil 50.0% 17.7% 350/100 bar, spray dry at 180/80 C Ti/To.
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps composition composition Water 64.5% Prepare HWP solution at 60 C, add HWP 205 16.7% 5.9% oligosaccharide and HMP solution, (preferably, Raftilose P95 31.7% 11.2% adjust pH of solution to 7.5, heat to 98 C and HMP RS400 1.7% 0.6% hold for 30 minutes, cool down to 60 C), add oil Tuna oil 50.0% 17,8% heated to 60 C, homogenise at 350/100 bar, Total 100.0% 100.0% spray dry at 180/80 C Ti/To.
Example 9: Formulations and Manufacture of Powders with 25% oil loading with blends of sodium caseinate with raw or processed resistant starch (potato starch) Ingredient powder emulsion Processing steps (using raw potato starch) composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Potato starch 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and mix Alanate 180 37.5% 5.8% with starch dispersion above. (Preferably heat Tuna oil 25.0% 3.8% protein-starch mixture in cans at 98 C-30 Total 100,0% 100.0% minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed potato composition composition starch Water 84.6% Prepare 10%TS starch dispersion at 70 C, Potato starch 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down. Prepare 15%TS NaCas Tuna oil 25.0% 3.8% solution at 60 C and mix with processed starch Total 100.0% 100.0% above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised potato starch) Water 84.6% Prepare 10%TS starch dispersion at 70 C, Potato starch 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, microfluidise at 800 bar-3 Tuna oil 25.0% 3.8% passes. Prepare 15%TS NaCas solution at 60 C
Total 100.0% 100.0% and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using extruded potato starch) composition composition Water 84.6% Prepare 10%TS extruded starch dispersion at Potato starch 37.5% 5.8% 70 C. Prepare 15%TS NaCas solution at 60 C
Alanate 180 37.5% 5.8% and mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in cans at Total 100.0% 100.0% 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 10: Formulations and Manufacture of Powders with 25% oil loading with blends of sodium caseinate with Hylon VII or pre-processed resistant starch (Hylon VII
Ingredient powder emulsion Processing steps (using Hylon VII starch) composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Hylon VII 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and mix Alanate 180 37.5% 5.8% with starch dispersion above. (Preferably heat Tuna oil 25.0% 3.8% protein-starch mixture in cans at 98 C-30 Total 100.0% 100.0% minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed Hylon composition composition VII starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS Prepare 15%TS NaCas Total 100.0% 100.0% solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder = emulsion Processing steps (using heat processed and composition composition microfluidised Hylon VII starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using extruded Hylon VII
composition composition starch) Water 84.6% Prepare 10%TS extruded starch dispersion at Hylon VII 37.5% 5.8% 70 C. Prepare 15%TS NaCas solution at 60 C
Alanate 180 37.5% 5.8% and mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in cans at Total 100.0% 100.0% 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 11: Formulations and Manufacture of Powders with 25% oil loading with blends of sodium caseinate with Hi-Maize 1043 or pre-processed resistant starch (Hi-Maize 1043) Ingredient powder emulsion Processing steps (using Hi-Maize starch) composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Hi-Maize 1043 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and mix Alanate 180 37.5% 5.8% with starch dispersion above. (Preferably heat Tuna oil 25.0% 3.8% protein-starch mixture in cans at 98 C-30 Total 100.0% 100.0% minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed Hi-composition composition Maize starch) Water 84.6% Prepare 20%TS starch dispersion at 60 C, Hi-Maize 1043 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS. Prepare 15%TS NaCas Total 100.0% 100.0% solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Hi-Maize starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hi-Maize 1043 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, __spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using extrude Hi-Maize starch) composition composition Water 84.6% Prepare 10%TS extruded starch dispersion at Hi-Maize 1043 37.5% 5.8% 70 C. Prepare 15%TS NaCas solution at 60 C
Alanate 180 37.5% 5.8% and mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in cans at Total 100.0% 100.0% 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dr at 180/80 C Ti/To.
Example 12: Formulations and Manufacture of Powders with 25% oil loading with blends of sodium caseinate with Novelose 260 or pre-processed resistant starch (Novelose 260) Ingredient powder emulsion Processing steps (using Novelose 260 starch) composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Novelose 260 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and mix Alanate 180 37.5% 5.8% with starch dispersion above. (Preferably heat Tuna oil 25.0% 3.8% protein-starch mixture in cans at 98 C-30 Total 100.0% 100.0% minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed composition composition Novelose 260 starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Novelose 260 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS. Prepare 15%TS NaCas Total 100.0% 100.0% solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Novelose 260 starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Novelose 260 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% IS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 84.6% Prepare 10%TS extruded starch dispersion at Novelose 260 37.5% 5.8% 70 C. Prepare 15%TS NaCas solution at 60 C
Alanate 180 37.5% 5.8% and mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in cans at Total 100.0% 100.0% 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 13: Formulations and Manufacture of Powders with 25% oil loading with blends of sodium caseinate with Novelose 330 or pre-processed resistant starch (Novelose 330) Ingredient powder emulsion Processing steps (using Novelose 330 starch) composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Novelose 330 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and mix Alanate 180 37.5% 5.8% with starch dispersion above. (Preferably heat Tuna oil 25.0% 3.8% protein-starch mixture in cans at 98 C-30 Total 100.0% 100.0% minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed composition composition Novelose 330 starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Novelose 330 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% IS. Prepare 15%TS NaCas Total 100.0% 100.0% solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Novelose 330 starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Novelose 330 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% IS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using extruded Novelose 330 starch composition composition Water 84.6% Prepare 10%TS extruded starch dispersion at Novelose 330 37.5% 5.8% 70 C. Prepare 15%TS NaCas solution at 60 C
Alanate 180 37.5% 5.8% and mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in cans at Total 100.0% 100.0% 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 14: Formulations and Manufacture of Powders with 25% oil loading with blends of sodium caseinate with Hylon VII or high pressure processed or ultrasonciated resistant starch (Nylon VII) Ingredient powder emulsion Processing steps (using Hylon VII starch) composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Hylon VII 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and mix Alanate 180 37.5% 5.8% with starch dispersion above. (Preferably heat Tuna oil 25.0% 3.8% protein-starch mixture in cans at 98 C-30 Total 100.0% 100.0% minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised x1 pass Hylon VII starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down,. add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-1 Total 100.0% 100.0% pass. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bars, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised x3 pass Hylon VII starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bars, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using extruded Hylon VII
composition composition starch) Water 84.6% Prepare 10%TS extruded starch dispersion at Hylon VII 37.5% 5.8% 70 C. Prepare 15%TS NaCas solution at 60 C
Alanate 180 37.5% 5.8% and mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in cans at Total 100.0% 100.0% 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bars, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using high pressure treated composition composition Hylon VII starch Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, HPP at 600 MPa, for 15 Total 100.0% 100.0% minutes. Prepare 15%TS NaCas solution at 60 C and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using ultrasound treated Hylon composition composition VII starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, US using 20 KHz unit @ 50 Total 100.0% 100.0% ml per minute, 380 Watts. Prepare 15%TS
NaCas solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 15: Formulations and Manufacture of Powders with 25% oil loading with unheated and heated blends of sodium caseinate with raw starches or pre-processed starch Ingredient powder emulsion Processing steps composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Waxy maize 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and Alanate 180 37.5% 5.8% mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in Total 100.0% 100.0% cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition corn osition Water 84.6% Prepare 20%TS starch dispersion at 70 C, Waxy maize 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, Microfluidise at 800 Total 100.0% 100.0% bar-1 pass. Prepare 15%TS NaCas solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Maize starch 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and Alanate 180 37.5% 5.8% mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in Total 100.0% 100.0% cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition Water 84.6% Prepare 20%TS starch dispersion at 70 C, Maize starch 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, Microfluidise at 800 bar-1 pass. Prepare 15%TS NaCas solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C) Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 84.6% Prepare 10%TS starch dispersion at 70 C.
Wheat starch 37.5% 5.8% Prepare 15%TS NaCas solution at 60 C and Alanate 180 37.5% 5.8% mix with starch dispersion above.
Tuna oil 25.0% 3.8% (Preferably heat protein-starch mixture in Total 100.0% 100.0% cans at 98 C-30 minutes, cool down to 60 C) Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps composition composition Water 84.6% Prepare 20%TS starch dispersion at 70 C, Wheat starch 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, Microfluidise at 800 Total 100.0% 100.0% bar-1 pass. Prepare 15%TS NaCas solution at 60 C and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C) Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 16: Formulations and Manufacture of Powders with 25% (lutein-in-oil) in heated and unheated blends of protein-sugar-starch as encapsulants Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare NaCas solution at 60 C, add DGS and Alanate 180 25.0% 7.7% starch, (preferably, adjust p-H of solution to 7.5, Maltostar 30 25.0% 7.7% heat to 98 C and hold for 34 minutes, cool down Tapioca dextrin 25.0% 7.7% to 60 C), add lutein heated to 90 C, homogenise K4484 at 350/100 bars, spray dry at 180/80 C Ti/To.
Lutein in oil 25.0% 7.7%
Total 100.0% 100.0%
Example 17: Formulations and Manufacture of Powders with 25% tributyrin in heated blends of protein-sugar or protein-sugar-RS starch as encapsulants Ingredient powder emulsion Processing steps composition composition Water 69.2% Prepare NaCas solution at 60 C, add sugars, Alanate 180 25.0% 7.7% (preferably, adjust pH of solution to 7.5, heat to Glucose 25.0% 7.7% 98 C and hold for 30 minutes, cool down to Maltostar 30 25.0% 7.7% 60 C), add tributyrin, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Tributyrin 25.0% 7.7%
Total 100.0% 100.0%
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Hylon VII starch) Water 69.2% Prepare 20%TS starch dispersion at 70 C, Alanate 180 25.0% 7.7% process in 73 x 82 mm cans at 121 C-60 Glucose 25.0% 7.7% minutes, cool down, add remaining water to Hylon VII 25.0% 7.7% make-up to 10% TS, micrvfluidise at 800 bar-3 Tributyrin 25.0% 7.7% passes. Prepare 15%TS NaCas solution at Total 100.0% 100.0% 60 C, add sugar and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add tributyrin, homogenise at 350/100 bars, spray dry at 180/80 C Ti/1b.
Example 18: Formulations and Manufacture of Powders with 25% tuna oil in heated blends of NaCas-sugar-HylonMF or NaCas-HylonMF or NaCas-StarPlus MF as encapsulants Ingredient powder emulsion Processing steps (using heat processed and composition com osition microfluidised Hylon VII starch) Water 69.2% Prepare 20%TS starch dispersion at 70 C, Alanate 180 25.0% 7.7% process in 73 x 82 mm cans at 121 C-60 Glucose 25.0% 7.7% minutes, cool down, add remaining water to Hylon VII 25.0% 7.7% make-up to 10% TS, microfluidise at 800 bar-3 Tuna oil 25.0% 7.7% passes. Prepare 15%TS NaCas solution at Total 100.0% 100.0% 60 C, add sugar and mix with processed starch above. (Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C).
Add tuna oil, homogenise at 350/100 bars, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Hylon VII starch) Water 84.6% Prepare 20%TS starch dispersion at 70 C, Hylon VII 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Star Plus A) Water 84.6% Prepare 20%TS Star Plus A dispersion at 70 C, Star Plus A 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Ingredient powder emulsion Processing steps (using heat processed and composition composition microfluidised Star Plus P) Water 84.6% Prepare 20%TS Star Plus P dispersion at 70 C, Star Plus P 37.5% 5.8% process in 73 x 82 mm cans at 121 C-60 Alanate 180 37.5% 5.8% minutes, cool down, add remaining water to Tuna oil 25.0% 3.8% make-up to 10% TS, microfluidise at 800 bar-3 Total 100.0% 100.0% passes. Prepare 15%TS NaCas solution at 60 C
and mix with processed starch above.
(Preferably heat protein-starch mixture in cans at 98 C-30 minutes, cool down to 60 C). Add oil heated to 60 C, homogenise at 350/100 bar, spray dry at 180/80 C Ti/To.
Example 19: Formulations and Manufacture of Powders with 25% tuna oil (+
Radiolabelled tracer) in heated blends of protein-sugar-RS starch as encapsulants for in-vivo testing.
Ingredient Ingredient emulsion Processing steps (using heat processed and Wt. (g) composition microfluidised Hylon VII starch) Water 82.47 82.04% Prepare 20%TS starch dispersion at 70 C, process Alanate 180 4.33 4.31% in 73 x 82 mm cans at 121 C-60 minutes, cool Glucose 4.33 4.31% down, add remaining water to make-up to 10% IS, Hylon VII 4.33 4.31% microfluidise at 800 bar-3 passes. Prepare 15%TS
Tuna oil 4.56 4.54% NaCas solution at 60 C, add sugar and mix with Radiolabelled 0.50 ml 0.50% processed starch above. (Preferably heat protein-tracer [14C] 18:3 (25 MCi) glucose-starch mixture in cans at 98 C-30 minutes, Total solids 18.05 18.0% cool down to 60 C). Add radiolabelled tuna oil, Total 100.52 100.0% homogenise at 350/100 bars, spray dry at 180/80 C Ti/To.
Characteristics of microcapsules in-vitro The properties of the example I formulations are shown in figure 1 of the drawings. Solvent-extractable fat in all powders (25% fat in powder) were less than 3% (of total fat) indicating that the encapsulating efficiency was good.
Released oil in SGF was less than 2% of total fat for all formulations. Released oil in SGF+SIF
were less than 4% of total fat for casein based microcapsules and up to 22% of total fat for WPI based microcapsules. In these examples NaCas based formulations offer better protection than WPI based formulations. Also heat treatment applied to WPI-sugar encapsulant can increase the release in SGF+SIF.
Depending on the type of protein and whether heat treatment is applied to the encapsulant the core may be released targeted to a specific site in the GI
tract.
The properties of the example 2 formulations are shown in figure 2 of the drawings. Solvent-extractable fat in all powders (50% fat in powder) were less than 3% (of total fat) indicating that the good encapsulating efficiency was maintained when that ratio of the fat to encapsulating material was increased from 1:3 in 25%
fat powders to 1:1 in 50% fat powders. Released oil in SGF was less than 2% of total fat for all formulations. Released oil in SGF+SIF were less than 4% of total fat for casein based microcapsules and up to 30% of total fat for WPI based microcapsules. The trend in the release properties of the microcapsules in Figure 2 with 50% fat powders mirror those observed in Figure 1 for 25% fat powders. In these examples NaCas based formulations offer better protection than WPI based formulations. Also heat treatment applied to WPI-sugar encapsulant can increase the release in SGF+SIF. Depending on the type of protein and whether heat treatment is applied to the encapsulant the core may be released targeted to a specific site in the GI tract.
The properties of the example 3 formulations are shown in figure 3 of the drawings. Formulations (25% fat powders) made with heated protein-starch as encapsulants had low solvent extractable fat (<1 % of total fat). Released oil in SGF was less than 2% of total fat for all formulations. Released oil in SGF+SIF
were less than 4% of total fat for casein based microcapsules and up to 12.5%
of total fat for WPI based microcapsules. In these examples NaCas based formulations offers better protection than the WPI based formulation.
Depending on the type of protein used the core may be released targeted to a specific site in the GI tract.
The properties of the example 4 formulations are shown in figure 4 of the drawings. Formulations (50% fat powders) made with heated protein-starch as encapsulants had higher solvent extractable fat (1 to 20 % of total fat) than corresponding formulation for 25% fat powders. Released oil in SGF was less than 2% of total fat for all formulations. Released oil in SGF+SIF were less than 5% of total fat for casein based microcapsules and up to 15% of total fat for WPI
based microcapsules. In these examples NaCas based formulations offer better protection than the WPI based formulation. Depending on the type of protein used the core may be released targeted to a specific site in the GI tract. Solvent-extractable fat in powder was not related to solvent extractable fat in SGF
and SIF
fluids.
The properties of the example 5 formulations are shown in figure 5 of the drawings. For 25% fat powders the use of gums in combination with protein -glucose/dried glucose syrup or protein -oligosaccharide as encapsulant resulted in powders with low extractable fat in powder (<3% of total fat) and in SGF (<2%
of total fat). Released oil in SGF+SIF were less than 7% of total fat for casein based microcapsules and up to 22.8% of total fat for WPI based microcapsules.
Caseinate-based formulations with gums released more fat (figure 5) than similar formulations without gum (Figure 1) after sequential exposure to SGF and SIF.
In these examples NaCas based formulations offer better protection than WPI based formulations. Depending on the type of protein used the core may be released targeted to a specific site in the GI tract.
The properties of the example 6 formulations are shown in figure 6 of the drawings. The trends observed for 50% fat powders containing gums in combination with protein-glucose/dried glucose syrup or oligosaccharide (Figure 6) are similar to those observed for compositions with 25% fat powders (Figure 5).
All formulations had low extractable fat in powder (<4% of total fat) and SGF
(<2%
of total fat). Released oil in SGF+SIF were less than 5% of total fat for casein based microcapsules and up to 23% of total fat for WPI based microcapsules.
The amount of oil released in 50% fat powders (Figure 6) is significantly more than that in 25% fat powders (figure 5) after sequential exposure to SGF and SIF for WPI
based formulations. In these examples NaCas based formulations offers better protection than WPI based formulations. Depending on the type of protein used the core may be released targeted to a specific site in the GI tract.
The properties of the example 7 formulations are shown in figure 7 of the drawings. Hydrolysed milk proteins can be used in place of whole proteins for encapsulation of oil. For 25% fat powders use of hydrolysed protein in combination with oligosaccharide and polysaccharide as encapsulant resulted in powders with low extractable fat in powder (<3% of total fat). Released oil in SGF was less than 9% of total fat for all formulations. Released oil in SGF+SIF was less than 12% in all formulations. While combinations of hydrolysed casein with oligosaccharide and polysaccharides were less effective for protecting oils from release in SGF+SIF compared to corresponding formulations with the parent protein (Na caseinate), the reverse trend was found with the use of hydrolysed whey protein with oligosaccharide and carrageenan (Compare Figures 5 and 7).
The properties of the example 8 formulations are shown in figure 8 of the drawings. For 50% fat powders use of hydrolysed protein in combination with oligosaccharide and polysaccharide as encapsulant resulted in powders with low extractable fat in powder (<3% of total fat). While solvent-extractable fat in powders (50% fat) was low, the hydrolysed casein-based formulation containing carrageenan released a significant amount of the oil in SGF (77% of total fat) and in SGF+SIF (51% of total fat). This formulation will be a suitable delivery system if the site for target delivery is the stomach or small intestine. Those containing hydrolysed casein or hydrolysed whey protein with high methoxy pectin were comparatively better at protecting their load than those with carrageenan with release in SGF+SIF less than 3% of total fat. In these examples HWP based formulation offers better protection than HCP based formulation. Depending on the type of protein-polysaccharide combination used the core may be released targeted to a specific site in the GI tract.
The properties of the example 9 formulations are shown in figure 9 of the drawings. The results show that 25% fat powders made with unheated and heated combinations of caseinate and raw or pre-processed potato starch had solvent-extractable fat of between 3-8% of total fat, which was generally higher than those made with combinations of proteins with sugar/dried glucose syrup or oligosaccharides. All formulations with potato starch have very low oil release in-vitro. Exposure to SGF resulted in release of <0.6% of total fat and sequential exposure to SGF and SIF resulted in between 4-8% of total fat being released.
The properties of the example 10 formulations are shown in figure 10 of the drawings. The results show that 25% fat powders made with unheated and heated combinations of caseinate and unprocessed or pre-processed Hylon VII had solvent-extractable fat of between 13-26% of total fat, which was generally higher than those made with combinations of proteins with sugar/dried glucose syrup or oligosaccharides or potato starch indicating that encapsulation efficiencies of formulations with Hylon VII were significantly lower. Use of Hylon VII that had been subjected to microfluidisation or extrusion prior to combination with protein improved encapsulation efficiency. All formulations with Hylon VII have very low oil release in-vitro. Exposure to SGF which results in hydration of the capsule resulted in minimal release of <0.8% of total fat and sequential exposure to SGF and SIF
resulted in between 3-7% of total fat being released.
5 The properties of the example 11 formulations are shown in Figure 11 of the drawings. The results show that 25% fat powders made with unheated and heated combinations of caseinate and unprocessed or pre-processed Hi-Maize had solvent-extractable fat of between 13-26% of total fat. Use of Hi-Maize that had been subjected to microfluidisation or extrusion prior to combination with protein 10 improved encapsulation efficiency. All formulations with Hi-Maize have very low oil release in-vitro. Exposure to SGF which results in hydration of the capsule resulted in minimal release of <1% of total fat and sequential exposure to SGF and SIF
resulted in between 4-6% of total fat being released.
15 The properties of the example 12 formulations are shown in figure 12 of the drawings. The results show that 25% fat powders made with unheated and heated combinations of caseinate and unprocessed or pre-processed Novelose 260 had solvent-extractable fat of between 14-25% of total fat. Use of Novelose 260 that had been subjected to microfluidisation prior to combination with protein improved 20 encapsulation efficiency. All formulations with Novelose 260 have very low oil release in-vitro. Exposure to SGF which results in hydration of the capsule resulted in minimal release of <1% of total fat and sequential exposure to SGF and SIF
resulted in between 2-6% of total fat being released. The characteristics of formulations with Novelose 260 were similar to those observed for formulations 25 with Hylon VII (Figure 10) or Hi-Maize (Figure 11), which like Novelose 260 (Figure 12) are RS2 type starches.
The properties of the example 13 formulations are shown in figure 13 of the drawings. The results show that 25% fat powders made with unheated and heated 30 combinations of caseinate and unprocessed or pre-processed Novelose 330 (an RS3 type starch) had solvent-extractable fat of between 13-33% of total fat.
Use of Novelose 330 that had been subjected to extrusion prior to combination with protein improved encapsulation efficiency. All formulations with Novelose 330 have very low oil release in-vitro. Exposure to SGF which results in hydration of the capsule resulted in minimal release of <1 % of total fat and sequential exposure to SGF and SIF resulted in between 3.1 - 8.0 % of total fat being released.
The properties of the example 14 formulations are shown in figure 14 of the drawings. The results demonstrate that pre-processing of starches using emerging food processing technologies (i.e. microfluidisation, high pressure processing or ultrasonication) and extrusion could improve the properties of starches used in combination with casein as delivery systems to the GI tract. Released oil in SGF
was less than 1.2% of total fat for pre-processed starches. Released oil in SGF+SIF was less than 10% in pre-processed starches. All pre-processed starches have lower oil released in-vitro compared to the formulation containing unprocessed starch.
The properties of the example 15 formulations are shown in figure 15 of the drawings. The results demonstrate that use of native non-RS starch and their pre-processed counterparts in combination with protein produced powders with solvent extractable fat of between 5.5-13.6% of total fat. Released oil in SGF was less than 2% of total fat. Released oil in SGF+SIF was between 12-14% (Figure 15), which was slightly higher than that observed when resistant starches were used in combination with protein for microencapsulation (See Figures 9-14).
The properties of the example 16 formulations containing lutein-in-oil are shown in figure 16 of the drawings. The results demonstrate that lutein was protected in the powder microcapsule (0.4-2.5% unencapsulated lutein). Released lutein in SGF
was also very low (2.5-4% of total lutein). Released lutein in SGF+SIF was between 34-51% (Figure 16).
The properties of the example 17 formulations containing tributyrin are shown in figure 17 of the drawings. All the tributyrin was released after sequential exposure to SGF and SIF in NaCas-sugar formulation, and up to 83% in NaCas-sugar-RS
starch formulation. These results suggest that formulation with RS starch has improved the protection of tributyrin in the GI tract.
The properties of the example 18 formulations containing 25% tuna oil in heated blends of NaCas-sugar-HylonMF or NaCas-HylonMF or NaCas-StarPlus MF as encapsulants are shown in figure 18 of the drawings. The results demonstrate that addition of Glucose into an NaCas-Hylon formulation can improve the encapsulation efficiency of the powder microcapsule without affecting the release in SGF and SGF+SIF. Use of acetylated starch (StarPlus A) or proprionylated starch (Starplus P) in place of Hylon in formulations containing resistant starch in combination with NaCas increased the release in SGF+SIF from 5% for Hylon to 12% and 25% for Star Plus A and StarPlus P respectively (Figure 18), but there was no difference in the amount of release in SGF.
Release characteristics of tuna oil microcapsules in-vivo The result of the in-vivo experiment (example 19 formulation) is shown in figures 19a and 19b of the drawings. Lumen contents were expressed as a percentage of dose of radioactivity given to indicate relative abundance between the treatment groups. The figures show the percentage of administered dose of radioactivity recovered after dosing with C14 trilinolenein as free oil after 4, 9, and 14 hours.
This includes lumen contents, tissue and faeces. Data is expressed as percentage of total lumen radioactivity to show relative distribution across the system.
All rats n=5 in each case except for fig 19b at 14 hours where n=4.
The results indicated that the treatment with microencapsulated oil at 9 hours resulted in greater caecum and colon (18% and 35%) radioactivity (Figure 19a) than treatment with free oil, where only about 5% in caecum at 4 hours and about 10% in colon at 4 hours, with minimal amounts of radioactivity at 9 hours (Figure 19b). Radioactivity levels in the lumen for the treatment with free oil were low at all time points, which indicates that even by 4 hours there may be significant uptake and metabolism to CO2. Overall the in-vivo study indicates that the process of microencapsulation was reasonably successful in protecting the fish oil against early uptake and metabolism in the stomach and upper GI tract. For the treatment with microencapsulated oils the recovery was high at 4 and 9 hours, and at these time points the radioactivity was either in the stomach at 4 hours or caecum and colon at 9 hours. High amounts in the caecum and colon indicates that the microencapsulated oil passed the small intestine without significant absorption.
For the free oil, smaller amounts reached the caecum and colon, primarily because the recovery of the given dose was low at all time points indicating greater metabolism. Even at 4 hour time point the oil had already transited the small intestine. There was little radiolabel retained in the tissues at 14 hour in either group, which indicates that conversion to endogenous lipids was not significant.
From the above those skilled in the art will see that the present invention provides a simple to use yet effective delivery vehicle to the colon as well as preserving sensitive core ingredients during storage and processing. Those skilled in the art will also realise that this invention can be implemented in a number of different embodiments by varying the encapsulant proteins and carbohydrates without departing from the teachings of this invention.
Claims (9)
1. A method of preparing microcapsules for use in storing storage unstable, therapeutic and nutritional agents for targeted delivery to predetermined locations in the gastrointestinal tract which includes the steps of:
a) selecting a nutritional or therapeutic oil, oil soluble or oil dispersible nutritional or therapeutic agent to form an oil phase b) dispersing a water soluble film forming protein and a treated resistant starch in the aqueous phase c) mixing component (a) with component (b) and homogenizing the mixture to obtain an oil-in-water emulsion d) optionally drying the emulsion to obtain a powdered formulation in which the nutritional or therapeutic oil or agent is surrounded by the component (b) thereby encapsulating the storage unstable, therapeutic or nutritional agent.
a) selecting a nutritional or therapeutic oil, oil soluble or oil dispersible nutritional or therapeutic agent to form an oil phase b) dispersing a water soluble film forming protein and a treated resistant starch in the aqueous phase c) mixing component (a) with component (b) and homogenizing the mixture to obtain an oil-in-water emulsion d) optionally drying the emulsion to obtain a powdered formulation in which the nutritional or therapeutic oil or agent is surrounded by the component (b) thereby encapsulating the storage unstable, therapeutic or nutritional agent.
2. A method as defined in claim 1 in which the treated resistant starch is a resistant starch which has been treated to increase the number of sugar reducing groups.
3. A method as defined in claim 1 in which the protein is selected from milk proteins.
4. A method as defined in claim 3 wherein the milk proteins are selected from the group consisting of casein and whey proteins.
5. An encapsulation material for use with storage unstable, therapeutic and nutritional agents which releases the therapeutic and nutritional agents in predetermined locations in the gastrointestinal tract and in which the encapsulation material is formed by combining a food grade treated resistant starch with a water soluble food grade protein.
6. An encapsulation material as claimed in claim 5 in which the treated resistant starch is a resistant starch which has been treated to increase the number of sugar reducing groups.
7. An encapsulation material as claimed in claim 5 in which the protein is selected from milk proteins.
8. An encapsulation material as claimed in claim 7 wherein the milk proteins are selected from the group consisting of casein and whey proteins.
9. An orally administrable nutritional or therapeutic product for delivery of a nutritional or therapeutic agent to the gastrointestinal tract in which the agent comprises an oil or an oil soluble or dispersible component which is encapsulated in a material as claimed in any one of claims 5 to 8.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003906417 | 2003-11-21 | ||
| AU2003906417A AU2003906417A0 (en) | 2003-11-21 | GI Tract Delivery Systems | |
| PCT/AU2004/001592 WO2005048998A1 (en) | 2003-11-21 | 2004-11-22 | G i tract delivery systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2545399A1 CA2545399A1 (en) | 2005-06-02 |
| CA2545399C true CA2545399C (en) | 2013-01-29 |
Family
ID=34596427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2545399A Active CA2545399C (en) | 2003-11-21 | 2004-11-22 | Protein-polysaccharide microcapsules for delivering active agents to the gi tract |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9592201B2 (en) |
| EP (1) | EP1684733B1 (en) |
| JP (1) | JP5008980B2 (en) |
| KR (1) | KR101149304B1 (en) |
| CN (1) | CN1893930B (en) |
| AT (1) | ATE525066T1 (en) |
| AU (1) | AU2004290456C1 (en) |
| CA (1) | CA2545399C (en) |
| ES (1) | ES2373937T3 (en) |
| NZ (1) | NZ546974A (en) |
| WO (1) | WO2005048998A1 (en) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5001834B2 (en) * | 2004-04-28 | 2012-08-15 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | Starch processing method |
| GB0503684D0 (en) * | 2005-02-23 | 2005-03-30 | Ici Plc | Emulsifiers and emulsions |
| WO2007034213A1 (en) * | 2005-09-24 | 2007-03-29 | Cambridge Applied Polymers Limited | Process for encapsulation of edible oil products with whey protein and encapsulated edible oil products |
| US7803413B2 (en) * | 2005-10-31 | 2010-09-28 | General Mills Ip Holdings Ii, Llc. | Encapsulation of readily oxidizable components |
| ES2365246T3 (en) | 2006-03-27 | 2011-09-27 | Nestec S.A. | MILK WHEY PROTEIN VEHICLE FOR THE SUPPLY OF AN ACTIVE AGENT. |
| US8221809B2 (en) | 2006-06-22 | 2012-07-17 | Martek Biosciences Corporation | Encapsulated labile compound compositions and methods of making the same |
| US8795721B2 (en) * | 2006-12-18 | 2014-08-05 | Eatlittle Inc. | Device for delivery of a substance |
| WO2008122965A2 (en) | 2007-04-04 | 2008-10-16 | Sigmoid Pharma Limited | Pharmaceutical cyclosporin compositions |
| EP2061587A1 (en) | 2007-04-26 | 2009-05-27 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
| EP2527360B1 (en) | 2007-06-04 | 2015-10-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US9186640B2 (en) | 2007-08-28 | 2015-11-17 | Pepsico, Inc. | Delivery and controlled release of encapsulated lipophilic nutrients |
| US8741337B2 (en) * | 2008-01-04 | 2014-06-03 | Aveka, Inc. | Encapsulation of oxidatively unstable compounds |
| FI122252B (en) * | 2008-01-04 | 2011-10-31 | Valio Oy | Composition for improving liver metabolism and diagnostic procedure |
| US20110020519A1 (en) * | 2008-01-04 | 2011-01-27 | Aveka, Inc. | Encapsulation of oxidatively unstable compounds |
| WO2009118282A2 (en) * | 2008-03-25 | 2009-10-01 | Novozymes A/S | Encapsulation of oxidation labile compounds |
| ES2627848T3 (en) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8387772B2 (en) * | 2008-06-09 | 2013-03-05 | Mitsubishi Electric Corporation | Missing step detection device of passenger conveyor |
| WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2238843A1 (en) * | 2009-02-26 | 2010-10-13 | DSM IP Assets B.V. | Compositions of fat-soluble active ingredients containing protein-polysaccharide conjugates |
| GB2483815B (en) | 2009-05-18 | 2013-12-25 | Sigmoid Pharma Ltd | Composition comprising oil drops |
| US20100307542A1 (en) * | 2009-06-05 | 2010-12-09 | Kraft Foods Global Brands Llc | Method of Reducing Surface Oil on Encapsulated Material |
| US9968564B2 (en) | 2009-06-05 | 2018-05-15 | Intercontinental Great Brands Llc | Delivery of functional compounds |
| US20100310726A1 (en) * | 2009-06-05 | 2010-12-09 | Kraft Foods Global Brands Llc | Novel Preparation of an Enteric Release System |
| US8859003B2 (en) * | 2009-06-05 | 2014-10-14 | Intercontinental Great Brands Llc | Preparation of an enteric release system |
| NL2003224C2 (en) | 2009-07-17 | 2011-01-18 | Friesland Brands Bv | Method for encapsulation of an edible oil, compositions comprising edible oil and the use thereof. |
| JP5911799B2 (en) | 2009-08-12 | 2016-04-27 | シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | Immunomodulatory composition comprising a polymer matrix and an oil phase |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| CN103987279A (en) * | 2011-11-10 | 2014-08-13 | 科劳弗股份有限公司 | Encapsulation of food ingredients supplements and pharmaceuticals |
| US20130202740A1 (en) | 2012-02-08 | 2013-08-08 | Pepsico, Inc. | Acidic Aqueous Product Comprising Oil-Containing Microcapsules and Method for the Manufacture Thereof |
| US20130251855A1 (en) * | 2012-03-21 | 2013-09-26 | Pepsico, Inc. | Aqueous product comprising oil-containing microcapsules and method for the manufacture thereof |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| FR2998175A1 (en) * | 2012-11-16 | 2014-05-23 | Agronomique Inst Nat Rech | PROCESS FOR THE PRODUCTION OF A DRY EMULSION POWDER CONTAINING AT LEAST ONE ACTIVE LIPOPHILIC PRINCIPLE, AND DRY EMULSION OBTAINED BY THIS PROCESS |
| US8859005B2 (en) | 2012-12-03 | 2014-10-14 | Intercontinental Great Brands Llc | Enteric delivery of functional ingredients suitable for hot comestible applications |
| CA2902348C (en) | 2013-02-25 | 2021-11-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| JP2016514671A (en) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists and uses thereof |
| JP2016514670A (en) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase receptor agonists in combination with other drugs |
| US10785991B2 (en) | 2013-04-19 | 2020-09-29 | Commonwealth Scientific And Industrial Research Organisation | Encapsulation method |
| WO2015054649A2 (en) | 2013-10-10 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| HUE053624T2 (en) | 2014-11-07 | 2021-07-28 | Sublimity Therapeutics Ltd | Compositions comprising cyclosporin |
| CN105495564A (en) * | 2015-08-17 | 2016-04-20 | 中山大学 | Nutritional emulsion, as well as preparation method and application thereof |
| CN108430461B (en) * | 2015-10-12 | 2021-10-29 | 浙江医药股份有限公司新昌制药厂 | Preparation method of high-stability microcapsule dry powder/particles containing fat-soluble nutrients with more double bonds |
| US9668991B1 (en) | 2015-12-09 | 2017-06-06 | International Business Machines Corporation | SCFA colonic composition |
| EP3402804A1 (en) | 2016-01-11 | 2018-11-21 | Synergy Pharmaceuticals Inc. | Formulations and methods for treating ulcerative colitis |
| WO2019121493A1 (en) * | 2017-12-20 | 2019-06-27 | Dsm Ip Assets B.V. | Spray-dried particle comprising polyunsaturated fatty acids |
| CN116920075B (en) * | 2023-09-15 | 2024-01-02 | 潍坊市人民医院(潍坊市公共卫生临床中心) | Enteral nutrient solution and preparation method thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4230687A (en) * | 1978-05-30 | 1980-10-28 | Griffith Laboratories U.S.A., Inc. | Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices |
| FR2527438B1 (en) * | 1982-05-26 | 1985-08-09 | Centre Nat Rech Scient | WALL MICROCAPSULES CONSTITUTED BY CROSSLINKED POLYHOLOSIDES AND THEIR PREPARATION PROCESS |
| US4755397A (en) * | 1986-12-24 | 1988-07-05 | National Starch And Chemical Corporation | Starch based particulate encapsulation process |
| US4844919A (en) | 1987-07-13 | 1989-07-04 | Nabisco Brands, Inc. | Concave shaped snack food and process for preparing same |
| GB8812490D0 (en) | 1988-05-26 | 1988-06-29 | Agricultural & Food Res | Delayed release formulations |
| US4999205A (en) * | 1989-08-17 | 1991-03-12 | Kalamazoo Holdings, Inc. | Curcumin complexed on water-dispersible substrates |
| US5436019A (en) | 1990-02-20 | 1995-07-25 | A. E. Staley Manufacturing Co. | Method of preparing reduced fat foods |
| US5387426A (en) | 1990-02-20 | 1995-02-07 | A.E. Staley Manufacturing Company | Method of preparing reduced fat foods |
| IL98087A (en) | 1990-05-04 | 1996-11-14 | Perio Prod Ltd | Colonic drug delivery system |
| GB9116610D0 (en) * | 1991-08-01 | 1991-09-18 | Danbiosyst Uk | Preparation of microparticles |
| AU4109493A (en) | 1992-04-20 | 1993-11-18 | Bruce K. Redding Jr. | Method and apparatus for the modification of starch and other polymers |
| US5547513A (en) | 1992-06-18 | 1996-08-20 | Opta Food Ingredients, Inc. | Starch-based texturizing agent |
| JP3217499B2 (en) | 1992-11-04 | 2001-10-09 | 三和興産株式会社 | Low calorie food |
| CA2176719C (en) | 1993-11-17 | 2007-09-18 | Geoffrey Anisson | Fatty acid delivery system |
| US5498439A (en) * | 1994-03-04 | 1996-03-12 | Arnhem, Inc. | Process for encapsulating the flavor with colloid gel matrix |
| US5952314A (en) | 1994-04-01 | 1999-09-14 | Demichele; Stephen Joseph | Nutritional product for a person having ulcerative colitis |
| US5444054A (en) | 1994-04-01 | 1995-08-22 | Abbott Labatories | Method of treating ulcerative colitis |
| DE69535432T2 (en) | 1994-04-22 | 2007-12-06 | Astellas Pharma Inc. | Colon-specific drug delivery system |
| DE4434877A1 (en) | 1994-09-29 | 1996-04-04 | Fresenius Ag | Process for the production of starch breakdown products |
| US6048563A (en) | 1994-12-21 | 2000-04-11 | Rhodia Inc. | Reduced viscosity, low ash modified guar and process for producing same |
| US6001408A (en) | 1995-10-13 | 1999-12-14 | Corn Products International, Inc. | Starch products having hot or cold water dispersibility and hot or cold swelling viscosity |
| WO1998009537A1 (en) | 1996-09-09 | 1998-03-12 | Kiwitech Limited | Acid casein or a non-toxic soluble salt thereof and high-methoxyl pectin polymer |
| JPH10324642A (en) | 1997-03-26 | 1998-12-08 | Meiji Seika Kaisha Ltd | Colic delivery composite |
| JP3213574B2 (en) | 1997-10-27 | 2001-10-02 | 日本食品化工株式会社 | Manufacturing method of starch material high in dietary fiber |
| US6013299A (en) | 1997-11-04 | 2000-01-11 | Nabisco Techology Company | Process for making enzyme-resistant starch for reduced-calorie flour replacer |
| BR9706494A (en) * | 1997-12-30 | 2000-10-31 | Ind E Com De Cosmeticos Natura | Reticulated wraps, process for preparing reticulated wraps containing a biologically active compound and liquid solution |
| DE19830375A1 (en) | 1998-07-08 | 2000-01-13 | K D Pharma Bexbach Gmbh | Microencapsulated unsaturated fatty acid or fatty acid compound or mixture of fatty acids and / or fatty acid compounds |
| US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
| PH12001000675B1 (en) * | 2000-04-04 | 2009-09-22 | Australian Food Ind Sci Ct | Encapsulation of food ingredients |
| SE517422C2 (en) | 2000-10-06 | 2002-06-04 | Bioglan Ab | Production of starch for parenteral administration in form of microparticles, comprises washing starch, dissolving in aqueous medium, and subjecting to molecular weight reduction by shearing |
| US6887493B2 (en) * | 2000-10-25 | 2005-05-03 | Adi Shefer | Multi component controlled release system for oral care, food products, nutraceutical, and beverages |
| US6737099B2 (en) | 2001-03-29 | 2004-05-18 | The United States Of America As Represented By The Secretary Of Agriculture | Process for the deagglomeration and the homogeneous dispersion of starch particles |
| US20050287276A1 (en) * | 2003-01-22 | 2005-12-29 | Durafizz, Llc | Microencapsulation for sustained delivery of carbon dioxide |
| US8871266B2 (en) * | 2003-10-01 | 2014-10-28 | Commonwealth Scientific & Industrial Research Organisation | Probiotic storage and delivery |
| US7815957B2 (en) | 2003-11-17 | 2010-10-19 | General Mills Marketing, Inc. | Cheese compositions and related methods |
| JP5001834B2 (en) | 2004-04-28 | 2012-08-15 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | Starch processing method |
| US20060008575A1 (en) | 2004-07-12 | 2006-01-12 | Armbrecht Alyssa L | Flowable topping compositions and methods of making and using same |
-
2004
- 2004-11-22 ES ES04797040T patent/ES2373937T3/en active Active
- 2004-11-22 CA CA2545399A patent/CA2545399C/en active Active
- 2004-11-22 AT AT04797040T patent/ATE525066T1/en not_active IP Right Cessation
- 2004-11-22 EP EP04797040A patent/EP1684733B1/en active Active
- 2004-11-22 JP JP2006540077A patent/JP5008980B2/en active Active
- 2004-11-22 NZ NZ546974A patent/NZ546974A/en unknown
- 2004-11-22 AU AU2004290456A patent/AU2004290456C1/en active Active
- 2004-11-22 WO PCT/AU2004/001592 patent/WO2005048998A1/en active IP Right Grant
- 2004-11-22 KR KR1020067011946A patent/KR101149304B1/en active IP Right Grant
- 2004-11-22 US US10/578,903 patent/US9592201B2/en active Active
- 2004-11-22 CN CN2004800372742A patent/CN1893930B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9592201B2 (en) | 2017-03-14 |
| CA2545399A1 (en) | 2005-06-02 |
| AU2004290456B2 (en) | 2007-02-22 |
| CN1893930A (en) | 2007-01-10 |
| EP1684733A4 (en) | 2008-06-11 |
| EP1684733A1 (en) | 2006-08-02 |
| ATE525066T1 (en) | 2011-10-15 |
| KR20060096508A (en) | 2006-09-11 |
| CN1893930B (en) | 2012-06-27 |
| NZ546974A (en) | 2008-06-30 |
| KR101149304B1 (en) | 2012-05-25 |
| JP2007511541A (en) | 2007-05-10 |
| JP5008980B2 (en) | 2012-08-22 |
| EP1684733B1 (en) | 2011-09-21 |
| WO2005048998A1 (en) | 2005-06-02 |
| AU2004290456A1 (en) | 2005-06-02 |
| AU2004290456C1 (en) | 2012-03-15 |
| US20070218125A1 (en) | 2007-09-20 |
| ES2373937T3 (en) | 2012-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2545399C (en) | Protein-polysaccharide microcapsules for delivering active agents to the gi tract | |
| Ribeiro et al. | Microencapsulation of polyphenols-The specific case of the microencapsulation of Sambucus Nigra L. extracts-A review | |
| JP6581649B2 (en) | Formulation containing particles | |
| KR20190026648A (en) | Compositions and methods for selective gastrointestinal tract delivery | |
| EP3319589A1 (en) | Composition comprising satiety-inducing particles | |
| EP3188713B2 (en) | Method of inducing satiety | |
| US20070082027A1 (en) | Compositions and methods for reducing food intake and controlling weight | |
| US20090247486A1 (en) | Composition for oral substance coating, covering material for oral substance, edible container and oral substance using the same | |
| EP4108095A1 (en) | Microcapsules containing gamma-aminobutyric acid | |
| US10499677B2 (en) | Plant-based enteric coating composition | |
| WO2008077402A1 (en) | Microcapsules | |
| US10881125B1 (en) | Taurine-containing composition for improving assimilation of compounds contained in ingestible items | |
| Vatandoust | Multiple Fortification of Salt with Zinc and Other Micronutrients | |
| NZ729004B2 (en) | Method of inducing satiety | |
| NO882311L (en) | GRANULATE CONTAINING GAMMA LINOLIC ACID, EICOSAPENTAIC ACID AND / OR DOCOSAHEXAIC ACID, PROCEDURE FOR ITS PREPARATION, ITS USE IN EDIBLE PRODUCTS AND A TABLET CONTAINING SAME. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |